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Abstract 
Breastmilk is the optimal source of infant nutrition, with exclusive breastfeeding provided 
until 4-6 months of age followed by the continuation of breastfeeding alongside 
nutritionally adequate complementary feeding. Breastmilk provides strong protection 
against infectious disease morbidity and mortality, particularly important for infants in low 
resources settings. However, some low resource settings such as South Africa have high 
prevalence of human immunodeficiency virus (HIV) infection, also among pregnant women. 
Over the last two decades, there have been ongoing debate regarding balancing the 
benefits of breastmilk and the risks of mother to child transmission of HIV (MTCT) through 
breastmilk. However, numerous large studies have shown that triple antiretroviral therapy 
(ART) substantially reduces the risk of MTCT during pregnancy and breastfeeding to less 
than 1%. The overwhelming evidence of maternal ART as optimal PMTCT, coupled with 
rapidly expanding global accessibility of ART, have resulted in HIV treatment guidelines now 
recommending universal, lifelong ART for all women (“Option B+”). During this time, 
accumulated evidence of the substantial mortality and morbidity risks of replacement 
feeding for children of HIV-infected mothers in resource limited settings, resulted in HIV 
infant feeding guideline shifts towards breastfeeding promotion (exclusive breastfeeding for 
4-6 months, with continued breastfeeding alongside complementary feeding) as the optimal
infant feeding choice in most settings. Following many years of pro-replacement feeding 
guidelines, South Africa in 2010 adopted breastfeeding as the new national infant feeding of 
choice for both HIV-infected and -uninfected mothers. In 2013, South Africa changed their 
national ART guidelines to Option B+ for PMTCT. However, since these dramatic policy 
shifts, there remain limited data on the breastfeeding practices of HIV-infected women 
under Option B+.  A literature review completed on the 14th January 2017 identified 76 
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articles. However, only 8 studies (11 articles) fit the inclusion criteria and were included in 
the review. Of those that were included, all but one study took place prior to 2013 and the 
Option B+ and promotion of EBF guideline change. Prior to the shift, estimates of EBF from 
one cohort study reported 26% at 3 months and a median duration of 1 month. A single 
study that took place after 2013 provided estimates of EBF up to 6-week follow-up being 
82%. However, the sample size in this study was very small, did not provide estimates for 
the entire 6 month duration of EBF, and South Africa had not yet implemented Option B+ at 
the time of their study. Our review indicated a need for updated estimates of EBF under the 
current policy and recommendation in South Africa.  
The aim of this study was to examine early infant feeding practices among HIV-infected 
women in South Africa, with a specific focus on the first 6 months of life. This was a 
longitudinal analysis of data from the Maternal and Child Health AntiRetroviral Therapy 
(MCH-ART) study which took place between 2013 and 2015 in a peri-urban community in 
Cape Town, South Africa. MCH-ART study participants were HIV-infected pregnant women 
attending their first antenatal clinic, who were initiating ART and provided informed 
consent; and they were followed up through 18 months post-delivery. Infant feeding data 
were collected through clinical record forms based on maternal interview.  
We found that of the 471 women enrolled for postnatal follow-up, 429 (91%) ever EBF. The 
median duration of EBF was 1.5 months (interquartile range, IQR 0.3-5.4); only 115/471 
(24%) infants were EBF for 4 months or longer. Within the first week of birth, 8% of women 
reported some breast health issues; this figure increased to 22% of all women by 6 weeks. 
Lactation issues were common in our study sample and were predictive of suboptimal EBF.  
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Taken together, the literature review illustrates the lack of current estimates of EBF among 
HIV-infected women receiving lifelong ART – while the results presented illustrates multiple 
lactation issues and perseverance of suboptimal EBF practices.  
For the children of HIV-infected women to benefit optimally from the current HIV and infant 
feeding guidelines, programmatic interventions are urgently needed to address lactation 
problems and support women at risk of suboptimal breastfeeding practices. 
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Background 
Knowledge regarding the beneficial and protective properties of breastfeeding on infants 
and adverse effects related to suboptimal breastfeeding are widely accepted and readily 
available. Newly released World Health Organization (WHO) recommendations reiterate 
that “mothers should exclusively breastfeed (EBF) for the first six months, introduce 
appropriate complementary feeds and continue breastfeeding until 24 months or beyond 
because of the many benefits for both mother and child” [1]. Breastfeeding in general and 
EBF in particular are key factors in reducing childhood mortality,[2] partly due to the 
provision of maternal antibodies that help protect infants from common childhood illnesses 
such as diarrhea and pneumonia [3]. A recent systematic review found that EBF infants were 
at an incrementally lower risk of all-cause mortality compared to infants who were 
predominantly, partially, or non-breastfed with the greatest risks observed in the latter two 
groups [4]. Breast milk is readily available and economical compared to formula milk, and 
further offers maternal health advantages including reductions in stress, risk of postpartum 
depression and some types of cancer [5].  If infants are EBF for the first 6 months, more than 
800,000 neonatal deaths could be prevented each year [6]. EBF provides all the nutrients 
infants need during the first 6 months of life [7]. Though EBF is the ideal feeding strategy for 
infants, the estimates of EBF remains low globally. According to the United Nations 
Children’s Emergency Fund (UNICEF), global prevalence of EBF remains low at 43% [8]. 
South Africa is no exception. A cross-sectional study involving the general South African 
population, sampling from a total of 40 health facilities in four provinces, described a 12% 
prevalence of EBF until 6 months; 40% of mothers had stopped all breastfeeding by one 
month [9].  
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Breastfeeding duration and the prevalence of EBF are likely to be particularly low among 
HIV-infected South African women. Following years of controversy regarding the optimal 
infant feeding choices for HIV-infected women and their uninfected children, the newly 
released WHO guideline for HIV infant feeding in the context of maternal triple 
antiretroviral therapy (ART) promotes breastfeeding for settings with high rates of 
childhood mortality and morbidity due to infectious causes – such as most of sub-Saharan 
Africa [1]. This aligns HIV infant feeding guidelines to those for the general population. 
Specifically, HIV-infected women should EBF for the first four to six months, then introduce 
complementary foods, and continue to breastfeed until at least 12 months [1].  
Early in the HIV epidemic in Africa, breastfeeding was controversial due to the risk of 
maternal to child transmission (MTCT) of HIV via breast milk. Indeed prior to 2010, South 
Africa distributed free formula milk for infants up to six months at public health facilities as 
part of the Prevention of Mother-to-Child transmission (PMTCT) strategy [10]. However, in 
response to the WHO infant feeding recommendations in 2010 [11], South Africa changed 
the infant feeding guidelines to recommend breastfeeding for all HIV-infected mothers [12]. 
Furthermore, building on substantial evidence high-lighting the benefits of breastfeeding 
among HIV-infected women and the substantial reduction in MTCT risk in the context of 
universal maternal ART, the WHO since 2013 recommended lifelong antiretroviral therapy 
(ART) to all pregnant and breastfeeding women, with the promotion of breastfeeding in 
areas with high risk of childhood infectious diseases, such as South Africa [13]. In response 
to these guideline changes, the South Africa National Department of Health withdrew the 
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free formula milk program and adopted breastfeeding as the optimal infant feeding strategy 
[14].  
Yet before these guideline changes, data from a South African randomized intervention 
study found that 40% of HIV-infected women had stopped all breastfeeding by 12 weeks 
postpartum despite breastfeeding support [14]. Reasons for early cessation of breastfeeding 
generally and EBF specifically differ substantially between individuals and settings. These 
can include the understanding of the term “exclusive” breastfeeding, cultural practices, and 
infants who cry or cannot sleep at night [15]. There are many possible reasons for 
breastfeeding mothers to switch to formula feeding or to start complementary feeding 
before six months. These poor EBF practices could severely impact child health and survival.   
Optimal breastfeeding with maternal ART is an important aspect of PMTCT strategies that 
seek to promote HIV-free survival in areas with high infectious mortality and morbidity in 
childhood, such as South Africa [1]. In addition to poor general uptake of breastfeeding and 
EBF in South Africa, additional challenges are likely to exist following years of conflicting 
feeding advice [16]. To truly optimize HIV-free survival among the children of HIV-infected 
women, current breastfeeding practices under the newly implemented guidelines need to 
be established. In addition, risk factors for early cessation of breastfeeding and EBF need to 
be identified to aid the urgently needed development of interventions that improve the 
rates of EBF among both HIV-infected and HIV-uninfected South African women.  
Study Aim  
The main purpose of this study is to investigate the prevalence and duration of EBF among 
HIV-infected women that have initiated ART as part of PMTCT care at the Gugulethu 
Midwife Obstetric Unit (MOU) in Cape Town, South Africa.  
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The study has two main objectives: 
OBJECTIVE 1: To describe the prevalence and duration of EBF among HIV-infected women 
receiving ART in the postnatal period 
OBJECTIVE 2: Identify potential maternal and environmental factors that contribute to early 
cessation of EBF among HIV-infected women receiving ART in the postnatal period 
Identifying and investigating indicators and predictors will allow public health workers to 
develop area specific programmatic interventions to improve duration of EBF among HIV-
infected women in peri-urban South Africa. 
Methodology  
Study design 
This study will be a secondary data analysis using data collected prospectively from the 
maternal and child health antiretroviral therapy (MCH-ART) cohort study (UCT HREC 
reference 451/2012, Appendix A), which enrolled participants from March 2013 to June 
2014 and followed up participants for 18 months. The study took place in a large public 
sector primary healthcare facility in Cape Town, South Africa. The healthcare facility is 
surrounded by high levels of poverty and unemployment, and high HIV prevalence [17]. The 
MCH-ART study used both observational and experimental components. The MCH-ART 
study had three interrelated phases: Phase 1 was a cross sectional evaluation of HIV-
infected women at their first antenatal visit at Gugulethu midwife obstetrics unit (MOU); 
Phase 2 was an observational cohort of women taken from Phase 1 that were eligible for 
ART initiation; and Phase 3 was a randomised trial of two different strategies for delivering 
ART to postpartum women. Phase 1 consecutively enrolled all HIV-infected pregnant 
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women attending their first antenatal visit in order to characterized the health status of HIV-
infected pregnant women seeking antenatal care at Gugulethu MOU [17]. Phase 2 included 
all of Phase 1 women who were eligible for ART initiation, followed up from their second 
antenatal clinic visit through their first postpartum clinic visit (conducted within 7 days 
postpartum) to provide detailed description of ART initiation and antenatal follow-up [17]. 
Women were approached at their last Phase 2 visit, to participate in Phase 3. Phase 3 was a 
randomised trial of two different strategies for delivering ART to women during the 
postpartum period: referral to the general adult ART services from 4-6 weeks postpartum 
(the local standard of care) or continued receipt of ART in the antenatal clinic [17]. Women 
in Phase 3 returned for 6 additional study visits at 6 weeks, 3, 6, 9, 12, and 18 months 
postpartum [17].  
The main aim of the MCH-ART study was to evaluate two different strategies for delivering 
HIV care and treatment services during the postpartum period. Data for the current study 
will come from baseline and longitudinal interview questionnaires conducted during 
pregnancy and in the early postpartum period until age of 6 months. The infant feeding 
questionnaire was based on a validated infant feeding questionnaire from other PMTCT 
studies. Questionnaires included in this study were those concerning infant feeding, 
maternal demographics and general health, and maternal mental health.  
Study population  
Inclusion criteria for MCH-ART included a minimum age of 18 year, maternal HIV infection, 
antenatal care sought at the Gugulethu MOU (Appendix B). The study population will be 
participants from Phases 2 and 3 of the MCH-ART study; inclusion criteria are limited to 
women in Phase 2 who presented with their infants for study follow-up before the age of 6 
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months. All those who participated in phase 3 postnatal follow up were included in this 
analysis.  
Data collection methods 
Data have been collected through the MCH-ART clinical record forms (CRFs). All MCH-ART 
CRFs were translated into isiXhosa and back translated to English by trained Xhosa-speaking 
staff. Study visits included interviewer administered questionnaires in private rooms and 
venipuncture for viral load testing [17]. The measure of EBF will be calculated from maternal 
interview data provided on the infant feeding CRF collected during visits up to 6 months 
(Appendix C and Appendix D).  
Data safety and monitoring 
As per MCH-ART protocol, participant data are anonymous, with only participant 
identification numbers that were systematically assigned; data were captured without 
personal information attached to the files. Database files are kept on a password encrypted 
external hard drive, locked in a safe at the study site and at the office at the University of 
Cape Town.   
Data analysis 
All statistical will be done using STATA SE version 12.0 (Stata Corporation, College Station, 
Texas). Descriptive statistics will be used to investigate the frequency of overall 
breastfeeding cessation practices with bar graphs, stacked column bar graphs, and tables. 
To test the relationship between duration of EBF and different maternal characteristics that 
may affect cessation time, a logistic regression model will be implemented using a combined 
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binary indicator for EBF of <4 months and ≥4 months. All analysis will be conducted by 
supervisor and summarized and interpreted by the student. 
Ethical Considerations  
Description of risks and benefits  
The Columbia University Medical Center Institutional Review Board (CUMC-IRB) and the 
University Of Cape Town Faculty Of Health Services Research Ethics Committee (UCT-HREC) 
have approved the MCH-ART study (Appendix A). This secondary analysis will only go 
through the UCT-HREC (Appendix E). There are no direct risks or benefits for this study 
because there is no direct contact, laboratory work, or follow up will be done directly with 
study participants; only secondary analysis of the de-identified data, as has already been 
collected.  
Informed consent process 
Participants for this study were consented through the MCH-ART consent process (Appendix 
F and Appendix G). The informed consent process was done with an interviewer in the local 
language (isiXhosa) with a standardized form. The standardized forms were translated 
English to isiXhosa and back to English by two different isiXhosa speakers. During the 
informed consent process, participants were educated on the study purpose and 
procedures and were given an opportunity to ask the interviewer questions regarding the 
study as well as their role. Participation was strictly voluntary. For the purposes of this 
study, no extra consent is needed.   
Privacy and confidentiality 
For this analysis, there will be no contact with participants.  
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In low-and middle-income countries (LMIC) where resources are limited and the burden of 
disease is high, infant mortality rates continue to be high. Since replacement feeding is not a 
safe option for most; benefits of breastfeeding, especially exclusively breastfeeding (EBF), 
are crucial for health and survival of both mother and infant [1]. The greatest child survival 
and health benefits of breastfeeding are seen among children who are EBF for the first 4-6 
months of life, with breastfeeding continued thereafter along with nutritionally adequate 
complementary foods [2].  
However, 2016 global rates of EBF remains at a low 43% according to the United Nations 
Children’s Emergency Fund (UNICEF) [3]. In areas of high childhood mortality risks due to 
infectious causes, such as South Africa, the benefits of breastfeeding and EBF are most 
evident yet EBF is not practiced widely [2].  
In the early years of the HIV pandemic, HIV-infected women were discouraged from 
breastfeeding to avoid mother-to-infant transmission of HIV (MTCT) [4]. In the past two 
decades there have been multiple drastic HIV infant feeding guideline changes [1, 5, 6], 
causing much confusion among health workers, women and their families [7-11].  
With ample evidence that triple antiretroviral therapy (ART) minimizes HIV transmission 
through breastfeeding [12-16], the World Health Organization (WHO) now recommends 
that all pregnant women be on life-long ART to achieve HIV viral suppression, thus 
preventing new paediatric infections (Option B+) [17]. Alongside these recommendations, 
the WHO HIV infant feeding guidelines have been updated to recommend breastfeeding as 
best infant feeding choice for HIV-infected women from settings with high infant mortality; 
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the recommendations are to EBF for the first six months of life, then continue breastfeeding 
thereafter along with providing nutritionally adequate complementary foods [1].  
South Africa has adopted Option B+ PMTCT approaches in 2015, and since 2010 promote 
breastfeeding (with EBF until 6 months) as the best national infant feeding choice for both 
HIV-uninfected and HIV-infected women [18]. The new, uniform infant feeding guidelines 
which align recommendations for both HIV-infected and uninfected women, may improve 
the consistency of breastfeeding encouragement and support across health-care settings 
and communities. In turn, increased uptake of breastfeeding may positively impact rates of 
EBF. In this new era of prevention of mother-to-child transmission (PMTCT) of HIV (with 
universal maternal ART) and infant feeding (with universal promotion of breastfeeding) in 
South Africa, previous estimates of EBF are obsolete. The improved and now uniform infant 
feeding guidelines in the context of widespread maternal viral suppression and thus low risk 
of breastfeeding-related MTCT may improve EBF rates – simultaneously, this combination 
might not be sufficient to bring successful breastfeeding practices to the PMTCT setting. It is 
therefore imperative that estimates of EBF are updated and that potential risk factors that 
may prevent uptake of and/or adherence to EBF practices in the current PMTCT era be 
identified. This can facilitate evaluation of the guideline’s implementation success, and 
allow the development of targeted interventions so that all infants can fully benefit from the 
new national strategies.  
Objectives 
The main objective of this review is to evaluate changes in estimates of EBF prevalence, 
duration and determinants among HIV-infected South African women over the last 20 years. 
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In particular, to evaluate if there have been improvements in these estimates under current 
recommendations of universal ART with encouragement of breastfeeding.  
METHODOLOGY  
Search strategy 
This literature review aims to identify the prevalence and duration of, and factors associated 
with, EBF in South Africa. The literature search was done (final search in Pubmed/MEDLINE, 
on 14 January 2017) restricted to English language without restriction on publication date. 
The search was narrowed down based on study population of interest (HIV-infected 
women), geographic location (South Africa), and whether any EBF estimates were presented 
(at least one of prevalence, duration, or potential predictors of EBF). The search terms were 
combined as (((“breastfeeding” OR “breastfed” OR “breastfeed” OR “breast feed”) AND 
(“exclusive” OR “exclusively”)) AND (((“HIV” AND (“positive” OR “infected”)) AND (“women” 
OR “mother”) AND “South Africa”) (Figure 1). Only original research studies in South Africa 
that provided estimates of EBF prevalence, duration, or predictors of cessation or uptake 
among HIV-infected women were included in this literature review, as shown in Figure 1 and 
summarized in Table 1. Excluded studies with reasons for exclusion are shown in Table 2. A 
single author conducted the search and extracted the data under supervision of a senior 
author. 
Definition of exclusive breastfeeding  
The WHO definition of EBF most commonly used globally is “only breast milk without any 
other liquids or solids, not even water, except for oral rehydration solution or drops or 
syrups of vitamins, minerals or medicines” [1]. Most of the studies included in this review 
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followed the WHO definition of EBF, with the exception of the Vertical Transmission Study 
(VTS) which “allowed water or formula milk to be given for up to three days” [19]. 
RESULTS 
The search strategy yielded a total of 76 articles on EBF among HIV-infected women in 
South Africa. Of these, 58 records were excluded (Figure 1 and Table 2) following screening 
of titles and abstracts. Eighteen full text articles were screened, of which 7 were excluded 
(no desired estimates, n=2; review article, n=2; did not provide separate indicators of SA 
EBF, n=1; no differentiation between HIV-infected or uninfected women, n=2). Eleven 
publications are included in the review, from 8 studies. These are summarized in Table 1. 
Prevalence of exclusive breastfeeding among HIV-infected women in South Africa  
Analysis from the Vitamin A study (randomized controlled trial of maternal vitamin A 
supplementation to HIV-infected pregnant women, South Africa 1995-1998; no access to 
ART), assessed MTCT risk by feeding practices from delivery to 3 months [4]. Among 391 
breastfeeding women, 191 (48.8%) EBF until one month then dropped to 103 (26.3%) EBF at 
three months [4]. The Vertical Transmission Study (VTS) was a large non-randomized 
intervention conducted in KwaZulu-Natal from 2001-2005; although the majority of HIV-
infected women and infants received single-dose Nevirapine for PMTCT, a few women 
enrolled after 2004 received ART for severe HIV-related disease. The VTS reported much 
higher prevalence of EBF among HIV-infected mothers – over 80% EBF at 1 month and 60% 
at 5.5 months [20]; they also found that the majority of women started EBF at birth (83%) 
[19]. Notably, the intervention for this study was intensive breastfeeding counselling and 
support throughout the early postpartum period. An observational cohort study of selected 
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PMTCT sites in South Africa conducted between 2002 and 2003, reported EBF prevalence of 
42% at 3 weeks [21]. In 2009, a cross sectional survey of 815 HIV-infected women, with a 
mean infant age of 4.5 months, found that 35.6% of women were EBF [22]. The prevalence 
of EBF among the women who participated in the cross-sectional survey had infants 
anywhere between three and six months old and difficult to determine age of infants when 
EBF ceased. Estimates of EBF have generally been low, except where intensive feeding 
counselling and support were provided in the VTS intervention. 
Duration of exclusive breastfeeding among HIV-infected women in South Africa  
In the Vitamin A trial, median duration of EBF was only one month [4], and the probability of 
still EBF at one month was only 0.49; 0.29 at 3 months, and only 0.04 at 6 months [23]. 
Similarly, in the observational study by Goga et al., it was reported that 130 women were 
EBF (42%) of the 309 women practicing any breastfeeding at three weeks, where-after the 
estimates dropped to 30% by 7 weeks and only 18% at 12 weeks [21]. Per contra, a report 
from the VTS by Coovadia et al. reported 83% of women EBF at birth, declining to 82% at 6 
weeks, 67% for at least 3 months, then only 40% EBF for 6 months with a median duration 
of EBF estimated at 159 days (IQR 122-174)[19]. A later analysis from the VTS demonstrated 
that among the 851 of 941 (90.4%) infants of HIV-infected women who had at least one day 
of EBF, the median duration of EBF was 175 days (IQR 137-180), or just under 6 months [20]. 
Another VTS analysis by Rollins et al. reported similar estimates up to 3 months; 81.4% of 
HIV-infected women were still EBF at 6-8 weeks, and 61.8% still EBF at 3-4 months [24] but 
they did not report estimates at 6 months. As can be seen from these findings of studies 
conducted prior to the introduction of current PMTCT guidelines, median duration of EBF 
varied from 3 weeks to 5.5 months in South Africa, bearing in mind that the 5.5 month 
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duration reported by the VTS study was within an intervention cohort providing 
comprehensive breastfeeding counselling and support. 
Risk factors for suboptimal feeding 
HIV-infected mothers face many challenges of adherence. Different studies in South Africa 
have identified various different factors that potentially affect EBF duration. Socioeconomic 
factors are often explored in relation to health outcomes and have commonly been 
associated with EBF. Having electricity appears to reduce the prevalence of EBF: hazard for 
cessation of EBF among VTS cohort participants [20]  was increased by 60% (adjusted 
Hazard Ratio, AHR 1.64 95% CI 1.24-2.17). Similar results were found in the Vitamin A study 
[25]. This is probably because women who have electricity have replacement feeding as an 
option because of the ease of preparation and refrigeration. The analysis of the Vitamin A 
study, at 14 weeks, reported fewer (57%) women who EBF had electricity compared to 
other groups (77%) combined [25] and the analysis of the VTS study also found that women 
who had electricity, gas, or paraffin (AOR 1.69 95%CI 1.16-2.46) were less likely to adhere to 
EBF intentions [26]. These findings suggest that women without electricity, gas or paraffin 
are more likely to EBF than those who do have electricity. This might be because women 
who have electricity, gas, or paraffin are able to easily boil water and also have 
refrigeration; they are able to easily prepare and store the replacement milk. They seem to 
appear of higher socioeconomic status and likely are also able to more easily afford to buy 
infant formula. While most studies found an association between having electricity has an 
effect on EBF, Coutsoudis et al. found that the duration of EBF was not consistently related 
to the socioeconomic indicators they investigated [4]. It is possible that the socioeconomic 
indicators they investigated were different than the ones the other studies used, or more 
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likely, that the extensive breastfeeding counselling and support negated the use of 
replacement feeding among those of higher socio-economic situations.  
Another risk factor that has emerged is maternal mental health. A retrospective cohort 
study found that prenatally depressed women were less likely to EBF at 6 weeks (adjusted 
odds ratio, AOR 0.68 95% CI 0.49-0.95) although EBF practices appeared not to be 
influenced by partum depression [27]. However, this study only looked at EBF until 6 weeks, 
not through six months of EBF, thus the effects of postpartum depression on later estimates 
of EBF may have been underestimated.  
An important risk factor for early EBF cessation is breast health concerns. An analysis of the 
VTS study between 2001 and 2003, which investigated the HIV transmission rate by infant 
feeding practices while providing intensive feeding support and home visits, found that 
reported breast problems can affect duration of EBF. The study reported breast health to be 
a major determinant of EBF cessation (AHR 4.12 95% CI 2.50-6.80) and that women who 
practice EBF experienced fewer breast health problems [20]. They also reported having 
feeding difficulties in the previous two weeks (AHR 1.75 95% CI 1.42-2.16) as increasing the 
hazard of EBF cessation [20].  
Many different risk factors emerged from these various studies in South Africa that may 
have affected prevalence and/or duration of EBF, some were similar while others were 
contradictory. However, there is consensus that HIV-infected women face many different 
challenges and factors that affect their infant feeding choices as well as duration of 
breastfeeding practices, although intensive breastfeeding counselling and support appears 
to enable women to surmount many of the obstacles to successful EBF.  
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Possible ways to fill in the gaps   
There have been numerous studies that have investigated intervention strategies that have 
shown to increase or improve prevalence and/or duration of EBF in South Africa. In the 
PMTCT intervention cohort of scheduled home visits, Bland et al found that at one month, 
HIV+ women who were part of the intervention group that received the scheduled number 
of home visits were more than twice as likely to still be EBF at that time (AOR 2.29; 95%CI: 
1.60–3.28) and again at two and four months, especially in HIV-infected women [20]. A 
more recent cluster randomized intervention trial by Ijumba et al. evaluated an integrated 
PMTCT package that included two visits during pregnancy and five postnatal home visits. In 
this study, the intervention was associated with doubling of exclusive breastfeeding (OR 
2.29, 95%CI 1.8-2.92 at 12 weeks postpartum [28]. 
It has been emphasized that better counselling support of EBF can improve EBF rates when 
counsellors are well informed [28]. In order for HIV-exposed infants to experience the full 
benefits of EBF through the new guidelines of Option B+, targeted intervention strategies 
have shown to improve EBF adherence and need to be developed and implemented in 
Option B+ PMTCT settings as soon as possible.  
Exclusive breastfeeding in Africa  
As these various studies in South Africa have illustrated, the prevalence of EBF among HIV-
infected women is extremely low in the absence of intensive breastfeeding counselling and 
support, and the duration is unacceptably short. However, low EBF rates among HIV-
infected women is not limited to South Africa; other countries in Africa, like Botswana, 
Zambia, Tanzania, Burkina Faso, Uganda, and Kenya, also experience similarly low 
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prevalence and short duration of EBF among HIV-infected women. A cross-sectional 
population-based study from Tanzania reported that the prevalence of EBF was 88.3% at 
one month, 65.5% at three months, and only 20.7% by 6 months [29]. An analysis of the 
MASHI study in Botswana, a clinical PMTCT trial, found that by 5 months, there was only 
17.5% of women still EBF [30]. In the Six Week Extended-Dose Nevirapine (SWEN) study, 
which analysed data from three randomized control trial from Ethiopia, India, and Uganda, 
reported a 28% EBF prevalence at six months in all three countries [31]. A study completed 
in an urban informal settlement in Nairobi, Kenya reported only 2% EBF at six months [32]. 
The median duration of EBF by study site in the multi-country Kesho Bora study, comparing 
different antiretroviral interventions in the prevention of MTCT in Burkina Faso, Kenya, and 
South Africa, was 3.4 months in Burkina Faso, 1.4 and 1.8 months in two cities in Kenya [33]. 
They reported the median duration of EBF in South Africa was 5.3 months, however, only 
65% of the combined South African cohorts were ever breastfeeding [33]. Comparable to 
the estimates from Kenya, the median duration for HIV-infected women in Zambia, during 
the early 2000s when Nevirapine was given during the time of delivery to decrease MTCT, 
was 1.5 weeks [34]. There are many possible factors that contribute to the prevailing low 
prevalence and duration of EBF in South Africa as well as Africa.   
Many common risk factors for early EBF cessation have been identified across Africa. In the 
cross-sectional study in Zambia, women were more likely to EBF if they have adequate 
knowledge of EBF (AOR 5.4 95%CI 2.5, 11.6), delivered in health facilities (AOR 3.0 95% CI 
1.7, 5.4), or not experienced breast health problems (AOR 6.6 95%CI 3.2, 13.6) [35]. Similarly 
to findings in South Africa, women in Western Tanzania with breast health problems in the 
first 6 months were 86% less likely to EBF compared to those that did not experience breast 
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health problems (OR 0.14 95% CI 0.07, 0.26) [35]. Another study in Tanzania identified that 
women are more likely to EBF up to six months if she receives advice on breastfeeding after 
delivery (AOR 2.6 95% CI 1.5, 4.6) [29]. A cross-sectional study in Ethiopia also found that 
women who receive antenatal and postnatal counselling were more likely to EBF than those 
who do not [36]. Mgongo et al. also reported that single women (AOR 0.4 95% CI 0.2, 0.9) 
and women who drink alcohol (AOR 0.4 95% CI 0.3, 0.7) are less likely to EBF up to six 
months compared to married/cohabiting women and those who do not drink alcohol [29]. A 
systematic review and meta-analysis of breastfeeding and maternal health outcomes found 
that there is not a clear and consistent association between breastfeeding and maternal 
depression [37]; this might however not be applicable to all settings and situations, as 
evidenced by recent South African data from Tuthill et al., which reported that prenatally 
depressed women were less likely to breastfeed at 6 weeks [27].  
Although EBF practices appear to be suboptimal in many settings in sub-Saharan Africa, it is 
not ubiquitous. For example, EBF is a common practice in Malawi. It has been postulated 
that EBF is not stigmatized because it is widely promoted and accepted within the general 
population [38], unlike the rest of SSA and specifically in South Africa. The Breastfeeding, 
Antiretroviral, and Nutrition (BAN) study in Malawi, which was a randomized control trial 
examining an antiretroviral and nutritional intervention among breastfeeding HIV-infected 
women, reported a high adherence rate of EBF at 24 weeks in all three groups: 90% in the 
infant-Nevirapine group, 89% for the maternal-antiretroviral, and 88% in the control group 
[39]. Women in the BAN study were individually advised on EBF and received group 
counselling sessions by the WHO standardized protocol on breastfeeding training and 
counselling [39]. Although EBF prevalence and duration remains largely undesirable across 
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most of Africa, the situation in Malawi does provide insight and optimism, suggesting that 
even in low-resource settings, it is possible to increase EBF rates. 
The various studies and data illustrated the dire situation of EBF in Africa which led to the 
present WHO recommendation of Option B+. However limited data exists for current 
estimates. Similarly to most other countries in Africa, South African EBF prevalence and 
duration among HIV-infected women were low and risk factors diverse, prior to the 2010 
shift in infant feeding practices and the 2013 shift towards ART-based PMTCT strategies.  
CONCLUSION 
Since the drastic shifts in feeding recommendations, data on EBF patterns among HIV-
infected women under the new PMTCT and ART guidelines are limited, in Africa and 
specifically in South Africa. Though HIV-infected women on ART are able and encouraged to 
breastfeed, many still do not. In examining the literature on current EBF estimates in South 
Africa, it can be concluded that current data, since the policy shift, is scarce. The data that 
are available are outdated and reported mixed results. Furthermore, risk factors for 
suboptimal infant feeding - particularly lack of or early cessation of EBF – among HIV-
infected women and their infants are unknown in the current era of PMTCT. Data are 
urgently needed to guide potential interventions in this setting and this population. 
Quantitative studies are necessary to provide estimates of current EBF rates while 
qualitative studies could further identify social, economic, and cultural factors that impede 
prevalence and duration of EBF.  
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Figure 1. Flowchart of study selection process 
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Table 2. Characteristics of studies excluded following full-text review 
First author Year of publication Title Journal Reason for exclusion 
Bobat 1997 Breastfeeding by HIV-1-infected women and outcome of their infants: a 
cohort study from Durban, South Africa 
AIDS Examined transmission rate between feeding 
methods. Estimates of HIV-infected and HIV-
uninfected mothers were not stratified by HIV status 
Bland 2002 Breastfeeding practices in an area of high HIV prevalence in rural South 
Africa 
Acta Paediatr Review of 2 different studies: longitudinal study and 
cross sectional study 
Bland 2003 Maternal recall of exclusive breast feeding duration Arch Dis Child Does not distinguish between HIV+ and HIV- women. 
EBF estimates are not stratified by HIV status 
Doherty 2005 Health system constraints to optimal coverage of the prevention of 
mother-to-child HIV transmission programme in South Africa: lessons 
from the implementation of the national pilot programme 
Afr Health Sci Review of PMTCT programme in SA   
Patel 2010 Breastfeeding, HIV status and weights in South African children: a 
comparison of HIV-exposed and unexposed children 
AIDS Does not provide EBF estimates of interest 
Cournil 2013 Relationship between mortality and feeding modality among children 
born to HIV-infected mothers in a research setting: the Kesho Bora study 
AIDS Does not provide separate indicators for SA EBF 
Rochat  2016 Exclusive Breastfeeding and Cognition, Executive Function, and 
Behavioural Disorders in Primary School-Aged Children in Rural South 
Africa: A Cohort Analysis 
PLoS Med Examined long term effects of EBF. Does not provide 
EBF estimates of interest  
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Exclusive breastfeeding (EBF) is the international gold standard for infant feeding in the first 
4-6 months of life. In sub-Saharan Africa, breastfeeding has been adversely affected by the 
HIV epidemic, due to breastmilk-associated mother-to-child transmission (MTCT) risk in the 
absence of triple antiretroviral therapy (ART). However, with rapidly expanding global 
accessibility of ART, HIV treatment and infant feeding guidelines now recommend universal 
ART for all women (“Option B+”) with breastfeeding as the optimal infant feeding choice in 
most settings. Data is scarce on breastfeeding practices in this context. This project seeks to 
describe early infant feeding practices among HIV-infected women initiating ART in an 
Option B+ PMTCT clinic in peri-urban Cape Town, South Africa. 
Methods 
The Maternal-and-Child-Health-Antiretroviral (MCH-ART) study (2013-2016) enrolled HIV-
infected women initiating ART in pregnancy; breastfeeding mother-infant pairs were 
followed until 18 months. Data were collected via interviews at scheduled study visits, 
including repeated measures of infant feeding practices (24-hour recall). EBF duration was 
defined from delivery date to date of last visit reporting EBF. A priori-defined maternal-
infant characteristics potentially associated with early EBF cessation (< 4 months/never) 
were evaluated using exploratory data analysis and multivariable logistic regression. 
Results 
Of 471 breastfeeding mother-infant pairs, 429 (91%) were ever EBF. Median duration of EBF 
was 1.5 months (interquartile range, IQR 0.3-5.4); only 115/471 (24%) were EBF for 4 
months or longer. Median maternal age was 28 years (IQR 24-32); 41% were married/co-
habiting; 58% delivered at primary care level. Within the first week of birth, 8% of women 
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reported some breast health issues, increasing to 22% of all women by 6 weeks. The most 
commonly reported lactation concern was cracked nipples (43/96 women, 45% of all 
lactation problems). After adjusting for maternal age, marital status, education, poverty, 
gravidity, place of delivery, anxiety and alcohol use, lactation concerns remained somewhat 
predictive of suboptimal EBF, adjusted OR (AOR) 1.70, 95% CI 0.93-3.14. 
Conclusions 
Exclusive breastfeeding is sub-optimal in this setting. Lactation problems are common, and 
associated with premature EBF cessation. Additional lactation support is urgently required 
in PMTCT settings promoting breastfeeding. 
Trial registration  
ClinicalTrials.gov NCT01933477 
KEY WORDS 
Exclusive breastfeeding; HIV; PMTCT; Africa  




Optimal breastfeeding practices are strongly associated with improved child survival and 
health across nations [1-3]. The greatest benefits of breastfeeding are seen among children 
who exclusively breastfeed (EBF) for the first 4-6 months of life, with breastfeeding 
continued thereafter along with nutritionally adequate complementary food [2]. Due to 
risks of mother-to-child transmission (MTCT) of HIV via breastmilk [4, 5], these 
recommendations have not been universally applied to HIV-infected women. Until recently 
the optimal feeding choice for HIV-exposed infants had been a widely debated global health 
dilemma [6-8]. Early World Health Organization (WHO) human immunodeficiency virus (HIV) 
infant feeding guidelines focused primarily on prevention of mother to child transmission of 
HIV (PMTCT), and included recommendations involving replacement feeding where 
“affordable, feasible, acceptable, sustainable and safe (AFASS)” with early, abrupt weaning 
when breastfeeding was the only option [3, 9]. Some national PMTCT programmes provided 
free infant formula to HIV-infected women during this time, including Botswana and South 
Africa [10]. 
However, in line with findings from the pre-HIV era [11], several large studies subsequently 
demonstrated substantial childhood mortality and morbidity associated with replacement 
feeding for HIV-exposed infants in most settings [3, 12-14]. Breastfeeding reduces the risk of 
these adverse outcomes, with evidence of a benefit gradient where mixed feeding 
(breastfeeding with other items) provides some protection while EBF provides optimal 
protection. A recent systematic review, analysing the effects of optimal breastfeeding on 
infant survival among HIV-unexposed infants, found an almost threefold higher mortality 
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risk among partially breastfed infants, RR 2.84, 95% CI 1.63–4.97, and a 14-fold higher risk 
among non-breastfeeding infants (RR 14.4, 95% CI 6.13–33.9), compared to EBF infants. 
[15]. Similar results have been described for HIV-exposed infants, with a consistent picture 
emerging of improved HIV-free survival among breastfeeding infants [16, 17]. In terms of 
infectious morbidity, a systematic review by Zunza et al. showed that HIV-exposed 
breastfeeding infants experienced less diarrhoea than those that are formula fed, risk ratio 
(RR) 0.31; 95% CI 0.13-0.74 [18]. In keeping with these findings, a large cohort study of HIV-
exposed South African infants [19] found that EBF offers higher diarrhoeal protection than 
predominant (adjusted hazard ratio (AHR) 1.38, 95%CI 0.96-1.97), partial (AHR 1.19, 95%CI 
1.02-1.53), and no breastfeeding (AHR 1.35, 95%CI 1.17-1.53).  
Concurrently, several large PMTCT studies demonstrated dramatic reductions in MTCT risk 
among women receiving triple antiretroviral therapy (ART) [14, 20, 21]. Accumulated 
evidence presented in a 2011 Cochrane review showed that MTCT can be less than 1% with 
maternal viral suppression under triple antiretroviral therapy (ART) during pregnancy and 
breastfeeding [22]. 
The primary focus of PMTCT and infant feeding guidelines had shifted to HIV-free child 
survival rather than only MTCT, and ART was increasingly available across resource-limited 
settings. Consequently, the WHO ART, PMTCT and HIV infant feeding guidelines were 
updated to reflect these encouraging findings, and now recommend lifelong triple ART for 
all pregnant and breastfeeding HIV-infected women (“Option B+” PMTCT strategy), with 
breastfeeding for at least 12 months (EBF for first 4-6 months) as optimal feeding choice in 
most settings where HIV is highly prevalent [23]. From the beginning of the HIV epidemic, 
conflicting changes in infant feeding guidelines for HIV-infected women and their infants 
P a r t  C .  A R T I C L E   P a g e  | 7 
 
resulted in health workers disseminating mixed messages to women [24]. Now, the infant 
feeding guidelines are the same for both HIV-infected and uninfected women. South Africa 
phased out free infant formula after 2010 [10], adopted Option B+ in 2015 and now 
promote breastfeeding (with EBF until 6 months) as best national infant feeding choice for 
both HIV-uninfected and HIV-infected women, provided the latter are receiving ART [25, 
26]. The new, uniform infant feeding guidelines which align recommendations for both HIV-
infected and uninfected women, may improve the consistency of breastfeeding 
encouragement and support across health-care settings; in turn, this may improve the rates 
of exclusive breastfeeding. 
Since 2013, substantial progress has been made in providing ART to pregnant and 
breastfeeding HIV-infected women across South Africa [27]. However little data exists on 
the successful implementation of the accompanying infant feeding recommendations. 
Indeed, there is reason to expect poor uptake of these recommendations, given the 
suboptimal breastfeeding statistics for the general South African population [28]. There are 
limited published data on EBF prevalence and duration among South African women 
receiving universal ART, as per the recently introduced guidelines. Furthermore, many 
widely recognized risk factors for suboptimal breastfeeding such as poor family support, 
maternal anxiety, depression and substance abuse may be particularly common among 
women recently diagnosed with HIV [29, 30]. Identification of indicators and predictors of 
EBF among this potentially vulnerable population will allow public health workers to 
develop area-specific programmatic interventions to improve breastfeeding practices under 
conditions of ART, with the aim to optimize HIV-free survival and health of HIV-exposed 
children. 
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The main objective of this analysis is therefore to describe the prevalence, predictors and 
duration of exclusive breastfeeding among HIV-infected South African women initiating 
universal, lifelong ART during pregnancy.  
Methodology 
Study design 
The Maternal and Child Health AntiRetroviral Therapy (MCH-ART) study was conducted 
between 2013 and 2015 in a peri-urban community in Cape Town, South Africa. The MCH-
ART study used both observational and experimental components. The MCH-ART study had 
three interrelated phases: Phase 1 was a cross-sectional evaluation of HIV-infected women 
at their first antenatal visit at Gugulethu midwife obstetrics unit (MOU); Phase 2 was an 
observational cohort of women taken from Phase 1 that were eligible for ART initiation; and 
Phase 3 was a randomised trial of two different strategies for delivering ART to postpartum 
women [31]. MCH-ART study design and procedures have been described in detail 
elsewhere [31]. In short, consecutively enrolled HIV-infected women seeking antenatal care 
and initiating ART during pregnancy were enrolled and followed through pregnancy, and 
with their breastfeeding infants until 18 months postpartum [31]. Besides interviews 
conducted in isiXhosa, MCH-ART study visits also included viral load testing, and maternal 
and infant anthropometry [31].  
This analysis used perinatal data collected during pregnancy and the first 6 months after 
birth. Women attended up to three antenatal visits, and between birth and 6 months, up to 
four visits. The postnatal visits occurred at approximately < 7 days, 6 weeks, 3 and 6 months 
since birth. Trained field workers interviewed mothers and completed questionnaires on 
maternal and infant characteristics and health. 
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Study setting  
Recruitment and enrolment into MCH-ART took place between April 2013 and June 2014 at 
a dedicated research site located next to but separate from the Community Health Centre 
and midwife and obstetric unit (MOU) in Gugulethu, a peri-urban township of Cape Town, 
South Africa. Study follow-up was conducted at the same research site. The health centre 
and MOU serve a broader community with high levels of poverty and unemployment. 
Limited breastfeeding and EBF data from the general population in South Africa show that 
88% of women initiate breastfeeding after birth, however, more than 70% of infants receive 
other liquids and food before six months of age, and only about 8% are EBF at six months 
[32, 33]. 
Study participants were enrolled from the midwife and obstetric unit (MOU), which 
functions as a 24-hour primary care obstetric unit. The MOU is currently certified as a baby-
friendly hospital [9, 34]. Referrals for complicated pregnancies and/or deliveries are made 
to nearby tertiary care centres including the Mowbray Maternity Hospital and Groote 
Schuur Hospitals; both centres have facilities for assisted and caesarean section deliveries, 
maternal and neonatal intensive care units, and kangaroo mother care units. Breastfeeding 
is promoted by health care workers, and lactation consultants are available on request. 
Study participants  
Inclusion criteria for prospective follow-up in MCH-ART included maternal HIV infection and 
ART initiation in pregnancy, with antenatal care sought at the Gugulethu MOU at a 
minimum age of 18 years (Appendix B). Maternal HIV status was ascertained and 
documented by trained HIV testing and counselling staff with two finger-prick rapid tests at 
the MOU. Maternal viral load was tested at study measurement visits for adherence 
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measurements, not as part of the inclusion criteria. Postnatal follow-up was limited to 
breastfeeding mother-infant pairs who presented for a neonatal study visit before the age 
of 2 months. From the 589 women followed through pregnancy, 471 women and their 
infants were eligible for postnatal follow-up and are included in this analysis (Figure 1).
Study measures 
Extensive infant feeding questionnaires were used to determine infant exposure to solid 
food or liquids other than breastmilk within 3 days after birth, and at each study visit (24-
hour recall). The infant feeding questionnaire was based on a validated infant feeding 
questionnaire from other PMTCT studies. Mothers were also asked to recall the infant’s age 
at first introduction of any item other than breastmilk or medicine, and to report any breast 
health related concerns, such as cracked nipples, engorgement, mastitis/abscess, and 
insufficient milk supply. Those who reported having stopped all breastfeeding were asked 
the principle reasons for breastfeeding cessation. Maternal depression was measured using 
the Edinburgh Postnatal Depression Scale (EDPS) at antenatal and postnatal study visits, a 
10-item self-reported screening questionnaire for depressive symptoms [35]. Antenatal 
maternal anxiety was measured and calculated using the Kessler Psychological Distress Scale 
(K-10), where items are scored between 1 and 5 [36]. The Alcohol Use Disorders 
Identification Test was used to identify hazardous alcohol consumption (AUDIT-C) [37]. 
Antenatal ultrasound measures were used to estimate gestational age, supplemented with 
reports of last menstrual period where indicated. Samples for maternal viral load testing 
were collected at each study visit for batched analysis.  
Data analysis  
Definitions: outcome 
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This analysis characterized EBF in accordance with the WHO definition, as “the infant 
receives only breast milk without any other liquids or solids, not even water, except for oral 
rehydration solution or drops or syrups of vitamins, minerals or medicines” [23]. 
Breastfeeding practices were defined cross-sectionally at each study visit, and categorized 
as no breastfeeding, some breastfeeding but not exclusively, or EBF. Loss of EBF status was 
considered irreversible. The last study visit at which EBF was reported was conservatively 
assumed to be the last day of any EBF, and the last study visit at which any breastfeeding 
was reported was taken as the last day of breastfeeding. Duration of EBF was defined as 
infant date of birth subtracted from date of visit with last reported EBF; for analysis, a 
combined binary indicator was created to indicate (1) EBF for 4 months or longer (“optimal 
EBF practices”), vs (2) never EBF or EBF for less than 4 months (“suboptimal EBF practices”). 
Definitions: potential risk factors 
Successful EBF is strongly related to lactation problems in the early postnatal period [38]. 
We categorized maternal complaints of breast health issues or maternal reasons for 
breastfeeding cessation into the following broad categories: painful or engorged breasts; 
cracked nipples; mastitis (painful or engorged breasts treated with antibiotics) or breast 
abscess; and/or maternal impression of inadequate breast milk supply (including maternal 
concerns regarding poor infant growth, excessive crying or small volumes of expressed 
breast milk).  
Generally, breastfeeding can be influenced by multiple maternal, infant and environmental 
factors [39]. For this analysis, we decided a priori to explore the association between 
exclusive breastfeeding and a variety of factors as follows: maternal enrolment 
characteristics included age; education (highest grade completed); marital status 
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(married/cohabiting with a partner vs. not married/cohabiting with a partner); degree of 
poverty (poverty score calculated using a standardized asset score based on dwelling type, 
access to a flush toilet, running water in the home, electricity, refrigerator, television, 
telephone; and combined with employment status); pregnancy intentions (unplanned 
pregnancy); parity and gravidity; and timing of HIV diagnosis with relation to index 
pregnancy. Maternal HIV disease severity close to delivery was expressed as HIV viral load 
<50 copies/ml. Antenatal mental health measures included: EPDS score ≥13 to identify 
women with major depressive symptoms [35]; maternal anxiety, a K-10 score of ≥21.5; 
hazardous drinking, AUDIT-C score ≥3. Birth and delivery characteristics included place 
(delivery at a primary care facility including the MOU vs. hospital facilities vs. delivery before 
arrival at a facility, BBA) and method (caesarean section vs. vaginal delivery at a facility vs. 
BBA vaginal delivery). Gestational age at delivery was categorized into ≥ 37 completed 
weeks; 34 to <37 weeks; and <34 weeks. Infant birth weight was abstracted from the Road 
to Health Booklet (patient-held record for South African children); those born at less than 
the 10th percentile expected for gestational age were classified as being “small-for-
gestational-age” (SGA). 
Analysis 
Exploratory data analysis was used to identify patterns of exclusive breastfeeding, including 
frequency tables and bar graphs. Relationships between EBF duration (as a continuous 
measure and binary) were explored using the chi2 statistic or t-tests as applicable. Logistic 
regression analysis was used to test relationships identified in exploratory analysis. Variables 
which improved model fit according to the Akaike’s Information Criterion were included in 
the final logistic regression model, working on the principle of parsimony. All analyses were 
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done using Stata 12.0 (StataCorp, College Station, TX, USA); estimates are presented with 
corresponding 95% confidence intervals. 
Sample size 
A specific power analysis was not indicated for this secondary data analysis, but all results 
are presented with 95% confidence intervals to demonstrate achieved precision [40]. 
Original sample size calculations were based on requirements to determine a significant 
difference between the MCH-ART main trial arms for the primary study aims [31]. 
Results 
Demographics 
Four-hundred-and-seventy-one breastfeeding mother-infant pairs were enrolled into 
postnatal follow-up and are represented in this analysis (Figure 1). The first postnatal study 
visit occurred at a median of 5 days after birth (interquartile range, IQR 4-7 days); the 
second study visit at 6 weeks (IQR, 6-6.1 weeks); third, at 3 months (IQR 3-3.1 months) and 
fourth, at 6 months (IQR 6-6.1 months). The total number of infant feeding data available 
was different at different study visits due to some attrition: at 1st, 2nd, 3rd and 4th study visits 
data was available for 471 (100%), 444 (94%), 372 (79%), and 407 (86%) mother-infant pairs, 
respectively. At enrolment, median maternal age was 28 years (IQR 24-32). Less than half of 
the women 193 (41%) were married or cohabiting with a partner and 25% had completed 
secondary school. More than half of the women (58%) delivered at a hospital; 
approximately a third (30%) had caesarean sections. At delivery, the median gestational age 
was 39 weeks (IQR 38-40); 88% delivered at ≥37 weeks. Overall, women who EBF for 4 
months or greater (median duration of EBF 6 months, IQR 6-6) were slightly older, and were 
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less likely to be employed, single, primigravida or to report antenatal depression/anxiety 
(Table 1). Almost a quarter (24%) of women who did not EBF/EBF<4 months reported any 
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EBF, exclusive breastmilk and medicine only; BF, breastfeeding: categories based on maternal self-
report with 24-hour recall 
Study visits at <7 days (median age 5 days, interquartile range/IQR, 4-7); 6 weeks (IQR, 6-6); 3 
months (IQR, 3-3) and 6 months (IQR, 5.9-6.1) 


































HIV-infected mother-newborn pairs 
screened for enrolment 
N=597 
 
x Never breastfed, n=89  
x Other exclusions, n=37  






Enrolled for postnatal study follow-up  
N=471 
Still breast feeding at first postnatal visit  
(<28 days after birth) 
n=470  
Stopped breastfeeding 
within a few days after 
delivery, n=1 
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1: Measure taken at study enrolment; 2: Measure taken during antepartum; 3: <10 percentile for birth weight  
 
Table 1. Characteristics of HIV-infected women and their HIV-exposed infants, by initiation and duration of 
exclusive breastfeeding in the first 6 months of life 
 EBF < 4 months or never EBF  (N=356) 





Age in years1 27.4 (24.1, 31.7) 28.9 (25.4, 33.6) 27.8 (24.5, 32.3) 
Married or cohabiting1 128 (36) 65 (57) 193 (41) 
Highest grade complete1 11 (10, 11.5) 11 (10, 11) 11 (10, 11) 
Employed1 146 (41) 38 (33) 184 (39) 
House/formal dwelling1 177 (50) 47 (41) 224 (48) 
Poverty score1 0.5 (-0.5, 1.3) 0.5 (-0.5, 1.3) 0.5 (-0.5, 1.3) 
Primigravida 70 (20) 12 (10) 82 (17) 
Intended pregnancy  100 (28) 33 (29) 133 (28) 
HIV diagnosis during this pregnancy 210 (59) 58 (50) 268 (57) 
Viral suppression <50 copies/mL1 269 (76) 88 (77) 357 (76) 
EPDS threshold ≥132  41 (12) 7 (6) 48 (10) 
K-10 threshold ≥21.52 25 (7) 2 (2) 27 (6) 
AUDIT-C threshold ≥32 31 (9) 11 (10) 42 (9) 
Delivery/birth characteristics  
Gestational age (weeks) 39 (38, 40) 39 (38, 40) 39 (38, 40) 
     Premature, ≤ 37 weeks 43 (12) 14 (12) 57 (12) 
Log10 HIV viral  1.6 (1.6, 1.7) 1.6 (1.6, 1.7) 1.6 (1.6, 1.7) 
Place of delivery    
     Primary care 138 (39) 48 (42) 186 (39) 
     Hospital care 207 (58) 64 (56) 271 (58) 
     Born before arrival  11 (3) 3 (3) 14 (3) 
Caesarean section delivery 105 (29) 36 (31) 141 (30) 
Female 184 (52) 50 (43) 234 (50) 
Infant birthweight (kg)  3.1 (2.8, 3.4) 3.2 (2.7, 3.4) 3.1 (2.8, 3.4) 
    Small for gestational age3 41 (12) 12 (10) 53 (11) 
Breastfeeding characteristics    
Put to breast within 1 hour of delivery 309 (87) 100 (87) 409 (87) 
Lactation issues in first 6 weeks of life 80 (24) 16 (15) 96 (22) 
Duration of EBF (in months) 1.4 (0.2, 2.9) 6.0 (6.0, 6.0) 1.5 (0.3, 5.4) 
Values are median (IQR) or n (%); Abbreviations – EBF: exclusive breastfeeding; BF: breastfeeding; GA: gestation 
age; EPDS: Edinburgh Postnatal Depression Scale – 10-item self-report scale to screen for postnatal depression; 
threshold used; K-10: Kessler Psychological Distress Scale, Items scored between 1 and 5; AUDIT-C: Alcohol Use 
Disorders Identification Test–Consumption, Included scores of questions 1-3 only




Overall, the median duration of EBF was 1.5 months (IQR 0.33-5.36). Although 91% of 
mother-infant pairs were EBF at the first study visit, only about a quarter (115, 24%) of 
women continued to EBF for 4 or more months. Proportions of mother-infant pairs 
practicing EBF vs. some breastfeeding vs. no breastfeeding at each study visit are shown in 
Figure 2. Only 2% of mothers had introduced infant formula milk (FF) in the first week but by 
3 months of age, 33% of infants were receiving FF (Figure 3) while 37 (10%) of infants had 
already received some solids. There were 409 (87%) babies breastfeeding within one hour of 
delivery (Table 1). Within the first week of birth, 8% of women reported some breast health 
issues, increasing to 22% of all women by 6 weeks. The most commonly reported lactation 
concern was cracked nipples (43/96 women, 45% of all lactation problems), followed by 
engorgement/painful breasts (Figure 4). In univariable analysis, various factors, seen in 
Table 2, were predictive of suboptimal EBF. However, after adjusting for maternal age, 
marital status, education, poverty, gravidity, place of delivery, anxiety and alcohol use, 
lactation concerns remained somewhat predictive of suboptimal EBF, adjusted OR (AOR) 
1.70, 95% CI 0.93-3.14; (Table 2). Overall, lactation issues appeared to mediate the 
relationships of many of the identified risk factors with EBF practices, although formal 
mediation analysis was not conducted. 
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Study visits occurred at <7 days (median age, 5 days with interquartile range, IQR 4-7); 6 weeks and 3 months of age. Cumulative proportions based on 
maternal self-report (24-hour recall at study visit) 
Figure 2. Proportion mother-infant pairs per breastfeeding category over time 
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Cumulative proportions, from maternal self-report (24-hour recall) at study visits; median age (interquartile range) at study visits 1-3 presented 
 































5 days (IQR 4-7) 6 weeks (IQR 6-6) 3 months (IQR 3-3)
Water/clear fluids Other dairy products
Infant formula Solids
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Self-reported breast health at first (median infant age, 5 days; interquartile range, IQR 4-7) and/or second study visit (median age 6 weeks, IQR 6-6) 






0 10% 20% 30% 40% 50%
N=96
Cracked nipples Engorgement
Insufficient milk supply Mastitis/abscess
Unspecified 
P a r t  C .  A R T I C L E   P a g e  | 21 
  
1: Measure taken at study enrolment; 2: Measure taken during antepartum; 3: <10 percentile for birth weight  
 
Table 2. Predictors of suboptimal exclusive breastfeeding (EBF) practices (EBF for less than 4 months or never 
EBF), among HIV-infected women: results from logistic regression analysis 
Predictors Univariable Multivariable 
 OR 95% CI aOR 95% CI 
Maternal age in years1 0.95 0.91 - 0.98 0.96 0.92 - 1.00 
Married/co-habiting1 0.43 0.28 - 0.66 0.50 0.31 - 0.79 
School grade1 0.99 0.85 - 1.14 0.86 0.73 - 1.03 
Poverty score1 1.20 0.99 - 1.45 1.21 0.98 - 1.51 
Primigravida 2.10 1.09 - 4.03 1.43 0.67 - 3.06 
Planned pregnancy 0.97 0.61 - 1.55 - - 
EPDS threshold ≥132 2.02 0.88 - 4.64 - - 
K-10 threshold ≥21.52  4.29 1.00 - 18.41 3.93 0.89 - 17.26 
AUDIT-C threshold ≥32  0.89 0.43 - 1.84 0.75 0.34 - 1.62 
Lactation issues in first 6 weeks of life 1.84 1.03 - 3.31 1.70 0.93 - 3.14 
Gestation at delivery 0.96 0.87 - 1.05 - - 
Primigravida 2.10 1.09 - 4.03 1.44 0.68 - 3.06 
Primary care delivery (reference) 1.00  - - 
   Hospital 1.12 0.73 - 1.73 1.40 0.88 - 2.24 
   BBA 1.28 0.34 - 4.77 2.20 0.55 - 8.76 
Vaginal delivery, facility (reference) 1.00  - - 
   Vaginal delivery, BBA 1.16 0.32 - 4.27 - - 
   Caesarean section 0.92 0.58 - 1.46 - - 
Infant gender (male vs female) 1.39 0.91 - 2.12 - - 
Small for gestational age3 1.12 0.57 - 2.21 - - 
Put to breast within 1 hour of delivery 0.99 0.53 - 1.84 - - 
OR: odds ratio; aOR: adjusted odds ratio from logistic regression analysis; CI – confidence interval; EPDS: Edinburgh 
Postnatal Depression Scale – 10-item self-report scale to screen for postnatal depression; threshold used; K-10: 
Kessler Psychological Distress Scale, Items scored between 1 and 5; AUDIT-C: Alcohol Use Disorders Identification 
Test–Consumption, Included scores of questions 1-3 only; BBA: born before arrival, delivery not in a facility  
 




In this novel study population, we describe good initiation of EBF with a sharp drop off after 
6 weeks, and suboptimal duration of EBF overall. Although 91% of mothers practiced EBF in 
the first few days of life, by 3 months almost half had introduced other items and only one 
quarter of women completed at least 4 months of EBF.  
These findings are in keeping with earlier EBF data among women from several other 
resource-limited settings. A prospective observational study in South Africa under previous 
PMTCT guidelines reported 18% EBF by 3 months [41] and similarly, the Vitamin A study 
reported that only 26% of HIV-infected South African women EBF for more than three 
months [42], possibly influenced by the then prevalent PMTCT recommendations of 
complete breastfeeding avoidance and free infant formula programme under “AFASS” 
principles. A study in the early 2000s in Zambia, which included HIV-infected and HIV-
uninfected women, reported a low 37% that were still EBF at four months [43], while in an 
analysis of the MASHI study in Botswana, Shapiro et al. reported that only 17.5% of HIV-
infected women still EBF at five months [44]. The multi-country SWEN (Six Week Extended-
dose Nevirapine) study, which analysed daily dose of nevirapine and the transmission rate 
of HIV through breastfeeding from three RCT in Ethiopia, India, and Uganda, reported a 28% 
EBF overall prevalence at six months [45], which is similar to our results at six months. The 
low prevalence of these studies are not unexpected, partly as a result of previous PMTCT 
recommendations for HIV-infected women and partly due to the known – substantial – 
social and contextual barriers against EBF that exist across most of Southern African 
populations [46, 47]. However, the low 6 months EBF prevalence in our cohort is concerning 
in the light of current PMTCT recommendations to promote and support EBF, especially as 
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our study population were women attending a BFHI facility, who had voluntarily chosen to 
breastfeed their infants and from whom more optimal breastfeeding practices might have 
been expected.  
Some studies in resource-limited settings have reported more favourable prevalence of EBF; 
of note is that these were studies centred on providing in-depth nutritional counselling with 
support for breastfeeding mothers. The Vertical Transmission Study (VTS) in 2001 to 2004 in 
South Africa reported 60% EBF at 5.5 months [38]. The Breastfeeding, Antiretroviral, and 
Nutrition (BAN) study in Malawi reported even higher prevalence of EBF among all three 
study groups: 90% in the infant-nevirapine group, 89% for the maternal-antiretroviral, and 
88% in the control group [48]. Results of these studies show that intense breastfeeding 
counselling and support could yield successful EBF results.  
In our cohort, the median duration of EBF was only 1.5 months, which is substantially 
shorter than the WHO recommendation of 6 months. This result is comparable to the 
Vitamin A study by Coutsoudis et al. in the late 1990s, which reported a median duration of 
1 month in a South African population of HIV-infected women [49]. The analysis of the 
multi-country Kesho Bora study [50], which compared different antiretroviral interventions 
in prevention of MTCT in Burkina Faso, two cities in Kenya, and rural and semi-urban cities 
in South Africa, reported dissimilar median durations of EBF by study sites, ranging from 1.4 
months in Kenya to 5.3 months in South Africa. It should however be noted that only 65% of 
the combined South African cohorts ever breastfed [51]. Overall, median durations of EBF 
appear to vary between countries and settings, but a consistent picture emerges of 
suboptimal EBF initiation and/or duration among populations without specific interventions 
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or counselling aimed at improving breastfeeding practices, even when the national infant 
feeding policies include EBF.  
Lactation issues were commonly reported in our cohort, and associated with suboptimal EBF 
practices. Between 2001 and 2004 when the PMTCT strategy was single-dose nevirapine 
coupled with EBF for six months, Bland et al. found that in South Africa the probability of 
early EBF cessation was strongly associated with lactation problems: breast health issues, 
AHR (adjusted hazard ratio) 4.12, 95% CI 2.50-6.80 and feeding difficulties, AHR 1.75, 95% CI 
1.42-2.16 were both factors strongly associated with increased hazard of EBF cessation [38]. 
A sub-group analysis from the PROMISE-EBF study reported that 21% of HIV-infected 
women experienced some form of breast issues in the first six weeks postpartum and were 
three times as likely to stop breastfeeding before three months, AOR 3.1, 95% CI 1.7-5.7 
[52]. Similarly, in Tanzania among both HIV-infected and HIV-uninfected women, 17% 
experienced breast issues during breastfeeding and those women were 86% less likely to 
EBF compared to women who did not experience those issues, OR: 0.14, 95% CI 0.07, 0.26 
[53]. Lactation and breast issues are common and strongly associated with early EBF 
cessation, despite substantial evidence that EBF support interventions are available and 
have been shown to be highly effective [54].  
Lactation issues can be overcome with adequate EBF support. The nonrandomized 
intervention control cohort (VTS) study found that women who were not EBF were more 
likely to have breast health issues than women who were EBF (time-dependent variable; 
AOR 1.4, 95% CI 1.13-1.87) [55]. The study, which achieved high rates of EBF, examined the 
effect of a counselling intervention strategy and found that most breast health issues 
occurred during the first month; and that breast health issues were inversely related to the 
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quality of support from the trained breastfeeding counsellors [55]. In this study, 
breastfeeding counsellors assisted the women with breastfeeding and diagnosed breast 
health issues before they become serious issues [55]. A cross-sectional study in Ethiopia 
found that women that were counselled postnatally were more likely to EBF than those that 
were not, AOR 2.12, 95 % CI 1.28, 3.54 [56]. If well-trained EBF support was available and 
provided to breastfeeding women, lactation issues could be minimized or diagnosed and 
treated as the breastfeeding counsellors did in the intervention cohort. In keeping with this, 
the PROMISE-EBF study showed that frequent peer counselling can improve EBF practice in 
Burkina Faso, Uganda, and South Africa [57]. The WHO guidelines adopted in South Africa 
recommends Option B+ for HIV-infected women with promotion and support of 
breastfeeding, EBF in particular [23]. Although removing the promotion of infant formula 
from the South African PMTCT programme has been a strongly positive step, our results 
indicate the need for more lactation support.  
Hospital delivery, marital status, and antenatal anxiety were associated with suboptimal EBF 
in our cohort. In our context, marital status is probably a marker of improved social and 
economic support. This is in keeping with findings from Tuthill et al, who demonstrated that 
women living with their mothers were more likely to EBF [58]. Our study also found that 
women who delivered in a hospital facility were more likely to sub-optimally EBF, possibly in 
part the residual result of more than a decade of health workers recommending complete 
breastfeeding avoidance by HIV-infected women and/or lack of quality breastfeeding 
counselling in large, busy postnatal wards. Women with antenatal anxiety may be less likely 
to continue breastfeeding due to fear of HIV transmission; conversely, maternal anxiety 
reduces self-efficacy as well as negatively affecting breast milk composition [59], even in the 
absence of maternal HIV infection. Identification of women at risk of peripartum mental 
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health problems is increasingly recognized as an important determinant of adherence to 
ART [29]; our data high-lights the additional importance of maternal mental health in terms 
of adherence to breastfeeding recommendations. Along with factors examined, timing of 
the study execution and the time of transition to policy of breastfeeding might possibly 
explain in part the study findings.  
Limitations 
Our measurements of infant feeding practices were based on maternal recall. Although the 
risk of recall bias is reduced when utilizing 24-hour recall, our estimates of EBF are likely to 
be overestimations, given the social desirability of EBF in PMTCT settings. Our data may also 
not be broadly generalizable. Study participants were limited to women who attended 
antenatal care (and therefore had received some infant feeding counselling), had voluntarily 
chosen to breastfeeding, and had returned for study follow-up. For these reasons, our 
findings may present an overestimation of EBF prevalence and duration for broader HIV-
infected populations in this setting. Despite this, we describe suboptimal EBF practices, 
which raises concern for the true practices in our PMTCT settings. South African 
breastfeeding and EBF practices are most suboptimal in peri-urban settings where high 
levels of employment exist and infant formula is widely available [57]; our study 
participants’ experiences and practices are unlikely to reflect practices in rural areas. As is 
expected in observational research, some attrition resulted in missing data, however, the 
total proportions of women with available data were high, and it is unlikely that those who 
did not return for follow-up represented more favourable breastfeeding practices. 
Breastfeeding is a complex anatomical, physical and social interaction between mothers, 
infants and their families and communities. In recognition of the complex nature of 
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breastfeeding, we evaluated multiple potentially influential factors despite some sample 
size limitations. Some of our estimates have low precision, and the role of chance must be 
considered when interpreting our point estimates. Nonetheless, our findings are in keeping 
with breastfeeding literature from non-HIV infected populations. 
Conclusions 
This study demonstrates that most HIV-infected women receiving care at a reasonably well-
resourced PMTCT program, which provides ART and actively promotes breastfeeding, still 
fail to maintain optimal EBF practices. Preventable and treatable lactation problems were 
highly prevalent. To optimize the benefits of current ART and infant feeding guidelines, 
programmatic interventions to target lactation problems and identify women at risk of 
practicing suboptimal breastfeeding are urgently needed. Further qualitative research could 
help identify and address obstacles that hinder optimal breastfeeding practices among HIV-
infected women and their families. 
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Appendix B – 
MCH-ART inclusion/exclusion criteria
Inclusion and Exclusion Criteria 
Phase 1: All HIV infected women booking for antenatal care at Gugulethu MOU who are: 
x Age 18 years or older 
x Documented HIV-infection according to two finger-prick rapid tests using different 
test types (per routine protocol in this setting) or documentation of HIV status for 
those women self-reporting HIV diagnosis.  
x Confirmed pregnancy according to urine pregnancy test, ultrasound or clinical 
assessment 
x Has not initiated triple-drug antiretroviral therapy or AZT for PMTCT during the 
current pregnancy 
x Able to provide informed consent for research (Informed Consent #1) 
Phase 2: All of the phase 1 women who were eligible to initiate lifelong ART 
x Consented and participated in Phase 1 
x Documented ART eligibility based on current local guidelines 
x Started or scheduled to start ART at Gugulethu MOU in the current pregnancy 
(women started on AZT for PMTCT during the current pregnancy are eligible) 
x Women who were previously receiving lifelong ART must have not used ART for at 
least 6 months.  
x Able to provide informed consent for research (Informed Consent #2) 
Phase 3: All of the phase 2 women who were breastfeeding their babies at the <7days 
postpartum study visit 
x Consented and participated in Phase 2 
x Initiated ART during the antenatal period 
x Currently breastfeeding within <7 days postpartum (with an allowable window of up 
to 28 days postpartum) 
x Willingness to be randomized and return for postnatal study visits 
x Able to provide informed consent for research (Informed Consent #3) 
Exclusion criteria 
Individuals meeting any of the following exclusion criteria at the point in the study will be 
excluded: 
x Not currently pregnant (Phases 1 and 2) or loss of pregnancy/neonate (Phase 3) at the 
time of eligibility determination  
x Intention to relocate out of Cape Town permanently during the study period (Phase 2 and 
3 only) 
x Any medical, psychiatric or social condition which in the opinion of the investigators would 
affect the ability to consent and/or participate in the study (all phases), including: 
o Refusal to take ART/ARVs
o Denial of HIV status
Appendix C – 
MCH-ART Phase 2, infant feeding 
intentions/practices questionnaire
MCH-ART: Infant feeding intentions/practices, Phase 2 <7days pp PID: 2 - __ __ __ __ - __ __ 
Xhosa-English Version 2.5, 18 Feb 2014 
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Visit Date: __ __/__ __ __/__ __ __ __ 
Ukuqalisa ukuncancisa 
Initiation of breastfeeding: 
1. Wakhe waluncancisa  ibele usana lwakho?
Have you ever given breast milk to your baby?
Hayi No = 0 Æ Gqithela ku Q5
  SKIP to Q5 
Ewe Yes = 1
2. Ulubeke nini usana ebeleni emva kokuba
ubelekile?
When did you put the baby to the breast after birth?
Kwiyure yokuqala  =1
Within the first hour 
Emva kweyure yokuqala ukya kwiyure ezi-12=2  
After the first hour and up to12 hours 
Emva kweyureezi-12 ukuya kwiyure ezi-24=3
After 12 hours and up to 24 hours 
Emva kweyure ezi-24 ukuya kwiyure ezi-48(usuku lwe-2)=4
After 24 hours and up to 48 hours (2nd day) 
Emva kweyure ezi-48 ukya kwiyure ezi-72(usuku lwe-3)=5
After 48 hours and up to 72 hours (3rd day) 
Emva kweyure ezi-72(emva kosuku lwe-3)=6
After 72 hours (After the 3rd day) 
3. Ubisi lokuqala ulunike usana okanye
ulikhamile walilahla?
Did you give the first milk to the baby or did you express
and discard it?
Ndilunikile usana=1
Gave the first milk 
Ndilikhamile,ndalulahla elokuqala=2
Expressed and discarded the first milk 
Omabini ndimnikile ndakhama=3
Both gave and expressed it 
Enye=4, cacisa:_____________
Other, specify 
4. Emva kwentsuku ezi-3 ubelekile,usana
lwanikwa enye into ngaphandle kobisi
lwebele?
Within the first three days after birth, was your baby
given anything to drink other than breast milk?
Hayi No = 0 Æ Gqithela ku Q6
  SKIP to Q6 
Ewe Yes = 1 
Andazi= 9  Æ Gqithela ku Q6
Don’t know   SKIP to Q6
5. Usana lwanika ntoni ukuba lincance
kwintsuku ezi-3 lubelekiwe?
What was the child given to drink within the first 3 days
after birth?
Rhangqa zonke awazingcamliswa
Read all, circle all that apply
a. Amanzi  Water
b. Amanzi aneswekile  Water with sugar (or glucose)
c. Amanzi anetyuwa Water with salt
d. Ubisi lwenkomo oluxutyiweyo  Diluted cow’s milk
e. Ubisi lwenkomo olungaxutywanga Not diluted cow’s milk
f. Ubisi olungumgubo labantwana Infant formula
g. Olungolunye ubisi olungumgubo Any other powdered milk
h. Ipapa  Any porridge
i. Isophu  Any soup
j. Nayaphi na into engemanzi ibiyinxalezye yesiko
Any liquid as part of a ritual.
k. Utywala  Alcohol
l. Iyeza lesintu  Traditional medicine
m. Amayeza angekhoyo kuluhlu  Non-prescribed medicine
chaza/specify:___________
n. Amayeza akuluhlu avunyiweyo  Prescribed medicine,
chaza/specify:___________
o. Ubusi Honey
p. Amanye  Other,
chaza/specify:___________
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6. Kwintsuku zokuqala usana lunikwe into
lungcamle;amaqabaza ento okanye
nganeno kunomlomo ogcweleyo?
Within the first days did the baby get anything to taste; a
few drops of something or less than a mouth full?
Hayi No = 0 Æ Gqithela ku Q8
  SKIP to Q8 
Ewe Yes = 1 
Andazi= 9  Æ Gqithela ku Q8
Don’t know   SKIP to Q8
7. Ukuba ewe,Yintoni eyanikwa usana
lungcamle kwintsuku ezi-3 luzzelwe.
If yes, what was the child given to taste within the first 3
days after birth
Rhangqa zonke awazingcamliswa
Read all, circle all that apply
a. Amanzi  Water
b. Amanzi aneswekile  Water with sugar (or glucose)
c. manzi anetyuwa Water with salt
d. Ubisi lwenkomo oluxutyiweyo  Diluted cow’s milk
e. Ubisi lwenkomo olungaxutywanga Not diluted cow’s milk
f. Ubisi olungumgubo labantwana Infant formula
g. Olungolunye ubisi olungumgubo Any other powdered milk
h. Ipapa  Any porridge
i. Isophu  Any soup
j. Nayaphi na into engemanzi ibiyinxalezye yesiko
Any liquid as part of a ritual.
k. Utywala  Alcohol
l. Iyeza lesintu  Traditional medicine
m. Amayeza angekhoyo kuluhlu  Non-prescribed medicine
chaza/specify:___________
n. Amayeza akuluhlu avunyiweyo  Prescribed medicine,
chaza/specify:___________
o. Ubusi Honey
p. Amanye  Other,
chaza/specify:___________
Ukukhumbula indlela zokondla usana 
Infant feeding recalls: 
8. Uyaluncancisa ibele usana lwakho kude
kube ngoku
Are you currently breastfeeding your baby
Hayi No = 0 
Ewe Yes = 1Æ SKIP TO Q14
9. Uluncancise ibele usana lwakho ixesha
elingakanani
For how long did you breastfeed your child?





Do not know 
10. Zeziphi izizathu ezibangele uyeke
ukuluncancisa usana/okanye ungaluncancisi
What were your reasons for stopping to breastfeed/not
breastfeed your child?
Read all, circle all that apply
a. Umsebenzi Work
b. Imfundo  Education
c. Ukugula,ngaphandle kwengxaki  zokuncancisa
Illness, other than lactation problems
d. Ingxaki zokuncancisa  Lactation problems
e. Usana alukhuli kakuhle  Child not grow well
f. Usana lukhala kakhulu Child crying a lot
g. Ubisi lwebele alwanelanga  Not enough breast milk
h. Andifuni ukumosulela ngentsholongwane
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11. Uyeke njani ukuncancisa?
How did you stop breastfeeding?
Andizanga ndancancisa=0 
Never breastfed  
Ndimlumlile kancinci ndamnika olunye ubisi emva kwentsuku 
ezimbalwa=1 
  Gradually changed to other replacement milk over a period of days 
Ndimlumlile kancinci ndamnika ubisi emva kweveki 
ezimbalwa=2
 Gradually change to other replacement milk over a period of weeks 
Ndimlumlile kancinci ndamnika ubisi mva kwenyanga 
ezimbalwa=3
   Gradually change to other replacement milk over a period of months 
Ndiluhambisile usana iintsuku ezimbzlw=4 
   Sent the child away for some days 
Ndiqabe into ebeleni usana alwalifuna ibele=5 
   Put something on breast to make child refuse breast 
Ndiluncancise ebusuku kuphela=6 
  Only breastfed at night 
Ndifumene iyeza  ekliniki  lokunqamla ubisi=7 
  Got medicine from clinic to stop milk 
Ndisebenzise iyeza lesi Xhosa lokunqamla/irati  
yokunqamla=8
  Took traditional medicine/remedy medicine to stop milk 
Lingcebiso/uxiizelelo ngabaye=9 
  Advice/pressure from others 
Ezinye=10,cacisa:_____________
  Other , specify 
12. Ikuthathe ixesha elingakanani ukumyekisa
umphelo?
How long did it take you to stop all breastfeeding?
Iintsuku: _______
Days 
13. Uceba ukuluncancisa olu sana kaphinda?
Are you planning on breast feeding this baby ever
again?
Hayi No = 0 
Ewe Yes = 1 
Andazi=9 
Don’t know 
14. Aye acandeka  aphuma ubumdaka
amabele,okanye wanengxaki emabeleni oko
uhte walubeleka usana ?
Have you had any infection, or problem with your
breasts since this child has been born?
Hayi No = 0 Æ Gqithela ku- 17 “dietary 24 hour recall”
  SKIP to Q17 
Ewe Yes = 1
15. Ukuba ewe,ngxakini le?
If yes, what problem did you have?
Funda zonke , urhangqe ezenzekileyo
Read all, circle all that apply
a. Ukudumba kwamabele
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16. Usana lwakho belunangaphi ukwenzeka kwa
le nto?
How old was your baby when this occurred?
Iintsuku :_______
Days 
Dietary 24hr recall We will now ask you some questions about your baby’s feeding since yesterday morning 
17. Ukuvuka kwakho izolo ekuseni kude ibe
kukuvuka kwakho namhlanje ekuseni uye
waluncancisa usana?
From the time you woke up yesterday morning till you
woke up this morning did you breastfeed your baby?
Hayi No = 0 Æ Gqithela ku- 20
  SKIP to Q20 
Ewe Yes = 1
18. Ukuvuka kwakho izolo ekuseni wade walala
ebusuku ,uluncancise kangaphi usana?
From the time you woke up yesterday morning till you
went to bed last night, how many times did you
breastfeed? 
a. _____________ amaxa
 # of times 
b. _____________ usana lulilela  ibele
 # of on demand feedings 
19. Ngelixesha uya kulala izolo kwade kwaba
kukuvuka kwakho namhlanje
ekuseni,uluncancise kangaphi usana?
From the time you went to bed last night till you woke up
this morning, how many times did you breastfeed?
c. _____________ amaxa
 # of times 
d. _____________ usana lulilela  ibele
 # of on demand feedings 
20. Ukuvuka kwakho izolo ekuseni kude kube
kukuvuka kwkho namhlanje
ekuseni:Ulunikile usana ezinye zezi zinto.
Rhangqa zonke omnike zona.
From the time you woke up yesterday morning till you
woke up this morning: Did you give any of the following
items to the child? 
Read ALL; please circle all that apply. 
Ukuba umnikile ,sixelele umnike  kangaphi?
And if you did, will you please tell how many times you 
gave it? 
a. Amanzi: Water, #_____
b. Amanzi aneswekile  Any water with sugar or glucose, # ____
c. Ijusi yeziqhamo Any fruit juice, # _____
d. Ingcambu emanzini  Any herbs in water, # _____
e. Iti engenabisi  Any tea without milk, # _____
f. Iti enobisi Any tea with milk, # _____
g. amanzi erayisi Rice water, # _____
h. Ubisi lwenkomo oluxutyiweyo  Diluted cow’s milk, # _____
i. Ubisi lwenkomo olungaxutywanga  # _____
Non diluted cow’s milk,
j. Ubisi olungumgubo labantwana Infant formula, # _____
k. Olungolunye ubisi olungumgubo  #_____
Other powdered milk,
l. Ezinye izinto njenge  yogati,itshizi,ikhrim # ___
Any other dairy product like yoghurt, cheese or cream,
m. Ubisi lwebhokhwe  Goat’s milk  # ___
n. Ipapa yabantwana,ipapa,okanye isonka,  # _____
Cereals, porridge or bread,
o. Iziqhamo/vegi  Any fruits/vegetables, # _____
p. Inyama ,intlanzi  Any meat or fish, # _____
q. Amaqanda  Eggs, # _____
r. iGripe water Gripe water, # _____
s. Amayeza abhalwe ngugqira
Any prescribed medicine, # _____
t. Amayeza angabhalwanga ngugqira,  # _____
Any non-prescribed medicine,
u. Into ebutywalara njenge bhiya,umqombothi, # _____
Any alcohol like beer or brew,
v. Ezinye, cacisa: _________________     #________
Other, specify
w. Nanye kwezi zikhankanywe ngentla
None of the above
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Formula feeding 
We would also like to ask you some questions about using infant formula milk 
21. Umnika umntwana ubisi lomgubo?
Is the mother formula feeding?
Hayi No = 0 Æ Gqithela ku-39 “leaving the child”
  SKIP to Q39 
Ewe Yes = 1 
22. Yeyiphi indlela eqhelekileyo yokunika usana
ubisi lomgubo?







Cup and spoon 
Ikomityi evulekileyo asele=3
Open cup and drinking 
Ikomityi enomngxunya wokusela=4 





23. Zingaphi ezinye zezi zinto  onazo
ezisetyenziselwa ukondla usana?
How many of each of the following items do you have
that are for infant feeding?
Nika inani lonazo ngento nganye.
Provide a number for each item that applies.
a. Ibhotile Bottles: # ___________
b. Ikomityi Cups :#_____________
c. Ikomityi zokondla ezinemingxuma yokusela
Feeding cups with drinking spouts: #________
d. Ititi Teats: #_____________
e. Ezinye, cacisa into : ______________ #______
Other, specify item
Kuyakhuthazwa ukuxuba/ulungise isidlo esinye sobisi lomgubo ngexesha, kwaye ungalugcini olushiyeluley ubisi, 
kodwa abanye omama bafumanisa kulula kwaye kungabizi ukuxuba ubisi olungu mgubo lwabantwana olwanele 
ngaphezu kwesidlo esinye, banika inxenye yobisi kwisidlo esinye kwaye bongele isininzi sobisi isidlo 
esilandelayo. Ngoku sizakubuza eminye imibuzo malunga nokuba ukukhetha ukuxuba kwaye utyise ngayo 
umntwana wakho amaxesha amaninzi: 
It is recommended to only mix/prepare one feed of formula milk at a time, and not store left over milk. However, some mothers find it easier, 
and cheaper, to mix enough formula for more than one feed; they give some of the milk for one feed and save the rest of the milk for the next 
feed. We are now going to ask some questions about how you choose to mix and feed your baby most of the time: 
24. Kukangaphi ngemini (iiyure ezi -24)ulungisa
ubisi lomgubo xa usana luza kuncanca.
(Kukangahpi uxuba ubisi lomgubo,hayi
amaxa omncancisa ngawo)
How many times during a day (i.e. in a 24 hour period) is the 
formula normally prepared for the child? (Number of times 
the formula is mixed, not number of times given) 
___________ amaxesha
times
25. Lubisi olungakanani lomgubo wabantwana
oqhele ukululungisa ngexesha elinye (hayi
ubungakanani obutyisa umntwana kwisidlo
esinye)?
How much formula is normally prepared at one time (not how 
much is fed to the baby in one feed)?
Mthundeza xa kuyimfuneko
Prompt when necessary. 
75ml 
100ml 




250ml (1 bhotile enkulu) 
500ml 
1 litre 
Eminye, cacisa :________________ (mls)
Other, specify
Andazi/ Don’t know = 9 
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26. Umncancisa ubisi lomgubo olungakanani
ngexesha?
How much formula is fed to the child each time?
______ (mls) 
27. Xa ubisi lomgubo wabantwana selulungisiwe
(luxutyiwe), ulubekaphi ubisi oselulungisiwe
kude ube uyamtyisa umntwana/phakathi
kokutyisa umntwana??
When the formula has been prepared (mixed), where is the 
prepared formula stored until/between feeding the baby? 
Mthundeze xa kuyimfuneko.








Flask: cooled first 
Andilugcini,ndilunika ngoko=5 





28. Anjani amanzi owenza ngawo ngesiqhelo
ubisi?
How was the water you use for the child’s formula feeds
normally prepared?
Aphendule kubekanye ungamthundezi
One response only, do not prompt.
Billisa phambi kokunika usana=1 
Boil before each feed 
Bilisa kanye ngemini agcinwe:egqunyiwe=2 









Bilisa,gcine amanzi ashushu eflaskini=7





29. Ubisi lomgubo ulufumana esibhedlele /kliniki
losana lwakho?
Are you currently receiving formula milk from the
hospital/clinic for your infant?
Hayi No = 0 ÆSKIP to Q32
Ewe Yes = 1 
30. Oko usana lwakho walubeleka ukhe waya
ekliniki uyokulanda ubisi wafumanisa
lungekho?
Since your baby was born have you been to the clinic to
collect milk and found that they were out of stock?
Hayi No = 0 Æ Gqithela ku-32
  SKIP to Q32 
Ewe Yes = 1 
31. Yenzeke kangaphi le nto oko walubeleka
usana?




32. Oko usana walubeleka  sewukhe
waluthenga ubisi?
Since your child’s birth have you purchased any formula
milk for your infant?
Hayi No = 0 
Ewe Yes = 1 
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33. Oko usana walubeleka wakhe waphelelwa
lubisi?
Since your child’s birth have you run out of formula
milk?
Hayi No = 0 Æ Gqithela ku-36
  SKIP to Q36 
Ewe Yes = 1 
34. Ithathe ixesha elingakanani?
How many days did this last?
Iintsuku :_______
Days
35. Uluncancise ntoni usana ngeli xesha?
What did you feed the baby during this time?
Rhangqa zonke omnike zona
Circle all that apply
a. Ubisi lwebele Breast milk
b. Ipapa  Porridge
c. Amanzi Water
d. Amanzi aneswekile Sugar and water
e. Iti Tea




36. Unalo ubisi lomgubo namhlanje endlini?
Do you have any formula in the house today?
Hayi No = 0 
Ewe Yes = 1 
37. Wakhe waluncancisa usana lwakho oko
waluzala ,umz.xa luza kulala,ebusuku
ebhedini,xa lulila?
Have you ever put your baby to the breast since birth
e.g. to go to sleep, in bed at night time, when crying?
Hayi No = 0 
Ewe Yes = 1 
38. Wakhe wabona ezikliniki amaphepha
apapasha ngobisi lomgubo?
Have you seen adverts at any health clinic advertising
formula milks?
Hayi No = 0 
Ewe Yes = 1 
Questions about leaving the child 
39. Sewukhe wohlukana nosana lwakho oko
walubeleka  kwenzeka ancanciswe ngomnye
umntu?
Have you ever been separated from your child since
childbirth so that someone else has fed the child?
Hayi No = 0 Æ SKIP TO Q41
Ewe Yes = 1 
40. Luye lwancanciswa ntoni usana oku
kokugqibela ungekho?
What did they feed the child the last time you were
away?
Rhangqa zonke ezenziweyo
Circle all that apply
a. Umxube wamanzi
Water based liquids
b. Umxube wobisi/ukutya okuthambileyo
Milk based liquids/semi-solid feeds
c. Ubisi lwam lwebele ebendilukhamile
My own expressed breast milk
d. Usana beluncanciswe ibele ngomnye umdlezana
The child was “wet nursed” (breastfed by another woman)
e. Ubisi lomgubo
Formula milk
f. Ukutya ebendikuhlafunile kosana
Food that I chewed for the baby
g. Andazi Do not know
h. Enye,cacisa : ___________________
Other, Specify
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Last questions about formula and breastfeeding: 
We will now ask you only five more questions about formula and breastfeeding 
41. Ngawaphi kulamayeza atyiwa lusana
lwakho:Which of these medicines is your
baby currently receiving:
Show the mother a range of possible medicines:
multivitamins, iron drops, nevirapine, cotrimoxazole, TB
treatment and antibiotics
Rhangqa zonke ezenziweyo
Circle all that apply





Sulphamethoxazole / Resmed / Iantibiotic ukukhusela






i. Umntwana akanamayeza awatyayo
Baby is not currently on any medication
42. Ebengakanani umntwana ukuqala kwakho
ukumnika ezinye izinto ngaphandla kwebisi
lebele okanye amayeza? Ngamany’amazwi,
ebengakanani yena xa wayeqala ukufumana
amanzi okanye ukutya okanye ubisi lomgubo
wabantwana?
How old was the baby when you FIRST gave him/her
anything other than breast-milk or medicine to drink? In
other words, how old when he/she first had any water or
food or formula milk?
Zange ndamnika enye into umntwana ngaphandle kwebisi 
lwebele = 0 ÆPhela apha/ END  
Have only given baby breastmilk and medicine since birth
OR 
Indicate age in weeks: #_______________________ 
Andiqinisekanga Unsure = 9 
43. Ukusuka kwixesha ovuke ngalo kusasa izolo
kude kuye ekuvukeni kwakho kusasa nje,
ubukhe wamnika umntwana wakho ubisi
olungumgubo lwabantwana?
From the time you woke up yesterday morning till you
woke up this morning did you give your baby any
formula milk?
Hayi No = 0 ÆPhela apha/ END 
Ewe Yes = 1
44. Ukusuka kwixesha ovuke ngalo kusasa izolo
kude  kubelixesha lakho lokulala,
umncancise kangaphi umntwana wakho
ubisi olungumgubo lwabantwana?
From the time you woke up yesterday morning till you
went to bed last night, how many times did you feed
your baby formula milk?
_____________ amaxa 
 # of times 
45. Ukusuka kwixesha ovuke ngalo kusasa izolo
kude  kube kukuvuka kwakho kusasa nje,
umncancise kangaphi umntwana wakho
ubisi olungumgubo lwabantwana?
From the time you went to bed last night till you woke up
this morning, how many times did you feed your baby
formula milk?
_____________ amaxa 
  # of times 
Date completed: __ __ /__ __ __ / __ __ __ __   Signed counsellor completing CRF: ___________________ 
Date of QC: __ __ /__ __ __ / __ __ __ __       Signed measurement nurse: ____________________ 
Appendix D – 
MCH-ART Phase 3, infant feeding 
intentions/practices questionnaire
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Infant feeding recalls: 
1. Are you currently breastfeeding your baby? No = 0 Yes = 1Æ SKIP to  Q7 




Do not know 
3. 
What were your reasons for stopping to 
breastfeed/not breastfeed your baby? 
Read all, circle all that apply
a. Work
b. Education
c. Illness, other than lactation problems
d. Lactation problems
e. Child not grow well
f. Child crying a lot
g. Not enough breast milk
h. Did not want to give my baby HIV infection
i. Advice/pressure from others
j. Other, specify: ____________________
4. How did you stop breastfeeding? 
Gradually changed to other replacement milk over a period 
of days = 1 
Gradually change to other replacement milk over a period 
of weeks = 2  
Gradually change to other replacement milk over a period 
of months = 3 
Sent the child away for some days = 4 
Put something on breast to make child refuse breast = 5 
Only breastfed at night = 6 
Got medicine from clinic to stop milk = 7 
Took traditional medicine/remedy medicine to stop milk = 8 
Advice/pressure from others = 9 
Other = 10, specify:____________________ 
5. How long did it take you to stop all breastfeeding? Days: _______ 
6. Are you planning on breast feeding this baby ever again? 
No = 0 
Yes = 1 
Don’t know = 9 
7. 
Have you had any infection, or problem 
with your breasts since this child has been 
born? 
No = 0 Æ SKIP to “Dietary 24hr recall” 10
Yes = 1 
8. If yes, what problem did you have? Read all, circle all that apply
a. Engorgement (swollen painful breasts)
b. Cracked nipples




g. Other, specify: ____________________
9. How old was your baby when this occurred? 
Days: _______ 
Weeks:_______ 
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Dietary 24hr recall 
We will now ask you some questions about your baby’s 
feeding over the last 24 hours 
10. From the time you woke up yesterday 
morning till you woke up this morning did 
you breastfeed your baby? 
No = 0 Æ SKIP to Q13
Yes = 1 
11. 
From the time you woke up yesterday 
morning till you went to bed last night, how 
many times did you breastfeed? 
a. _____________# of times
b. _____________ # of on demand feedings
12. 
From the time you went to bed last night 
till you woke up this morning, how many 
times did you breastfeed? 
a. _____________# of times
b. _____________ # of on demand feedings
13. 
From the time you woke up yesterday 
morning till you woke up this morning: Did 
you give any of the following items to the 
child? Please circle all that apply. 
And if you did, will you please tell how 
many times you gave it?  
a. Water, #_____
b. Any water with sugar or glucose, # ____
c. Any fruit juice, # _____
d. Any herbs in water, # _____
e. Any tea without milk, # _____
f. Any tea with milk, # _____
g. Rice water, # _____
h. Diluted cow’s milk, # _____
i. Non diluted cow’s milk, # _____
j. Infant formula, # _____
k. Other powdered milk,  #_____
l. Any other dairy product like yoghurt, cheese or cream, # ___
m. Goat’s milk, # _______
n. Cereals, porridge or bread, # _____
o. Any fruits/vegetables, # _____
p. Any meat or fish, # _____
q. Eggs, # _____
r. Gripe water, # _____
s. Any prescribed medicine, # _____
t. Any non-prescribed medicine, # _____
u. Any alcohol like beer or brew, # _____
v. Other, specify: __________     #________
w. None of the above
Formula Feeding 
We would also like to ask you some questions about using 
infant formula milk 
14. Is the mother formula feeding? 
No = 0 Æ SKIP to “leaving the child” Q32
Yes = 1 
15. 
What is the usual way that you feed the 
child formula milk? 
Prompt when necessary. 
Bottles = 1 
Cup and spoon = 2 
Open cup and drinking = 3 
Cup with drinking spout = 4 
Other = 5 
Don’t know = 9  
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16. 
How many of each of the following items 
do you have that are for infant feeding?  
Provide a number for each item that 
applies. 
a. Bottles: # ___________
b. Cups :#_____________
c. Feeding cups with drinking spouts: #________
d. Teats: #_____________
e. Other, specify item: ______________
#_________ 
17. How many times during a day (i.e. in a 24 
hour period) is the formula normally 
prepared for the child? (Number of times 




How much formula is normally prepared at 
one time? 
Prompt when necessary. 
75ml 
100ml 




250ml (1 big bottle) 
500ml 
1 litre 
Other, specify:________________ (mls) 
Don’t know 
19. How much formula is fed to the child each 
time? ______ (mls) 
20. 
Where is the prepared formula stored? 
Prompt when necessary. 
Room; covered = 1 
Room; uncovered =  2 
Refrigerator = 3 
Flask: cooled first = 4   
Do not store, give it directly = 5 
Other = 6, specify___________________ 
Don’t know = 9 
21. 
How was the water you use for the child’s 
formula feeds normally prepared? 
One response only, do not prompt. 
Boil before each feed = 1 
Boil once a day and store it: covered = 2 
Filter = 3 
Allow to settle = 4 
Bleach = 5 
Nothing = 6 
Boil, store hot water in flask = 7 
Other = 8, specify: _________________ 
Don’t know = 9 
22. Are you currently receiving formula milk 
from the hospital/clinic for your infant? 
No = 0 
Yes = 1 
23. Since your baby was born have you been 
to the clinic to collect milk and found that 
they were out of stock? 
No = 0 Æ SKIP to Q25
Yes = 1 
24. How many times has this happened since 
your baby was born? ______# of times 
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25. Since your child’s birth have you 
purchased any formula milk for your 
infant? 
No = 0 
Yes = 1 
26. Since your child’s birth have you run out of 
formula milk? 
No = 0 Æ SKIP to Q29
Yes = 1 
27. How many days did this last? Days: _________ 
28. 
What did you feed the baby during this 
time? 









29. Do you have any formula in the house 
today? 
No = 0 
Yes = 1 
30. Have you ever put your baby to the breast 
since birth e.g. to go to sleep, in bed at 
night time, when crying? 
No = 0 
Yes = 1 
31. Have you seen adverts at any health clinic 
advertising formula milks? 
No = 0 
Yes = 1 
Questions about leaving the child 
32. Have you ever been separated from your 
child since childbirth so that someone else 
has fed the child? 
No = 0 Æ SKIP to Q34
Yes = 1 
33. 
What did they feed the child the last time 
you were away? 
Circle all that apply
a. Water based liquids
b. Milk based liquids/semi-solid feeds
c. My own expressed breast milk
d. The child was “wet nursed” (breastfed by another
woman)
e. Formula milk
f. Food that I chewed for the baby
g. Do not know
h. Other, Specify: ___________________
Last questions about formula and breastfeeding: 
We will now ask you only five more questions about milk feeding
34. 
Which of these medicines is your baby 
currently receiving: 
Please show the mother a range of possible 
medicines: multivitamins, iron drops, nevirapine, 
cotrimoxazole, TB treatment and antibiotics
Circle all that apply







h. Other – specify________________
i. Baby is not currently receiving any medicine
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35. 
How old was the baby when you 
FIRST gave him/her anything other 
than breast-milk or medicine? 
# weeks old __________________ 
OR 
Have only given baby breast-milk and medicine since birth 
= 0 Æ END
1. Unsure = 9 Æ END
36. 
From the time you woke up yesterday 
morning till you woke up this morning 
did you give your baby any formula 
milk? 
Hayi No = 0 Æ END 
Ewe Yes = 1 
37. 
From the time you woke up yesterday 
morning till you went to bed last night, 
how many times did you feed your 
baby formula milk? 
 ____________# of times
38. 
From the time you went to bed last 
night till you woke up this morning, 
how many times did you feed your 
baby formula milk? 
____________# of times 
Date completed: __ __ /__ __ __ / __ __ __ __   Signed counsellor completing CRF: _________________ 
Date of QC: __ __ /__ __ __ / __ __ __ __  Signed measurement nurse: _________________ 
MCH-ART: Infant feeding intentions/practices, Phase 3 3, 6, 9 & 12 mo pp PID: 3 - __ __ __ __ - __ __ 
Version 3.1, 29 September 2013 
Page 1 of 5 Initials of counsellor: ________ 
Visit Date: __ __/__ __ __/__ __ __ __
Infant feeding recalls: 
1. Are you currently breastfeeding your baby? No = 0 Yes = 1Æ SKIP to  Q7 




Do not know 
3. 
What were your reasons for stopping to 
breastfeed/not breastfeed your baby? 
Read all, circle all that apply
a. Work
b. Education
c. Illness, other than lactation problems
d. Lactation problems
e. Child not grow well
f. Child crying a lot
g. Not enough breast milk
h. Did not want to give my baby HIV infection
i. Advice/pressure from others
j. Other, specify: ____________________
4. How did you stop breastfeeding? 
Gradually changed to other replacement milk over a period 
of days = 1 
Gradually change to other replacement milk over a period 
of weeks = 2  
Gradually change to other replacement milk over a period 
of months = 3 
Sent the child away for some days = 4 
Put something on breast to make child refuse breast = 5 
Only breastfed at night = 6 
Got medicine from clinic to stop milk = 7 
Took traditional medicine/remedy medicine to stop milk = 8 
Advice/pressure from others = 9 
Other = 10, specify:____________________ 
5. How long did it take you to stop all breastfeeding? Days: _______ 
6. Are you planning on breast feeding this baby ever again? 
No = 0 
Yes = 1 
Don’t know = 9 
7. Have you had any infection, or problem with your breasts since we last saw you? 
No = 0 Æ SKIP to “Dietary 24hr recall” 10
Yes = 1 
8. If yes, what problem did you have? Read all, circle all that apply
a. Engorgement (swollen painful breasts)
b. Cracked nipples




g. Other, specify: ____________________
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Dietary 24hr recall 
We will now ask you some questions about your baby’s feeding over 
the last 24 hours 
10. From the time you woke up yesterday morning 
till you woke up this morning did you breastfeed 
your baby? 
No = 0 Æ SKIP to Q13
Yes = 1 
11. 
From the time you woke up yesterday morning 
till you went to bed last night, how many times 
did you breastfeed? 
a. _____________# of times
b. _____________ # of on demand feedings
12. 
From the time you went to bed last night till you 
woke up this morning, how many times did you 
breastfeed? 
a. _____________# of times
b. _____________ # of on demand feedings
13. 
From the time you woke up yesterday morning 
till you woke up this morning: Did you give any 
of the following items to the child? Please circle 
all that apply. 
And if you did, will you please tell how many 
times you gave it?  
a. Water, #_____
b. Any water with sugar or glucose, # ____
c. Any fruit juice, # _____
d. Any herbs in water, # _____
e. Any tea without milk, # _____
f. Any tea with milk, # _____
g. Rice water, # _____
h. Diluted cow’s milk, # _____
i. Non diluted cow’s milk, # _____
j. Infant formula, # _____
k. Other powdered milk,  #_____
l. Any other dairy product like yoghurt, cheese or cream,
# ___
m. Goat’s milk, # _______
n. Cereals, porridge or bread, # _____
o. Any fruits/vegetables, # _____
p. Any meat or fish, # _____
q. Eggs, # _____
r. Gripe water, # _____
s. Any prescribed medicine, # _____
t. Any non-prescribed medicine, # _____
u. Any alcohol like beer or brew, # _____
v. Other, specify: __________     #________
w. None of the above
Formula Feeding 
We would also like to ask you some questions about using infant 
formula milk 
14. Is the mother formula feeding? 
No = 0 Æ SKIP to “leaving the child” Q32
Yes = 1 
15. 
What is the usual way that you feed the child 
formula milk? 
Prompt when necessary. 
Bottles = 1 
Cup and spoon = 2 
Open cup and drinking = 3 
Cup with drinking spout = 4 
Other = 5 
Don’t know = 9  
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16. 
How many of each of the following items do you 
have that are for infant feeding?  
Provide a number for each item that applies. 
a. Bottles: # ___________
b. Cups :#_____________
c. Feeding cups with drinking spouts: #________
d. Teats: #_____________
e. Other, specify item: ______________
#_________ 
17. How many times during a day (i.e. in a 24 hour 
period) is the formula normally prepared for the 
child? (Number of times the formula is mixed, 
not number of times given) 
___________ times 
18. 
How much formula is normally prepared at one 
time? 
Prompt when necessary. 
75ml 
100ml 




250ml (1 big bottle) 
500ml 
1 litre 
Other, specify:________________ (mls) 
Don’t know 
19. 
How much formula is fed to the child each time? ______ (mls) 
20. 
Where is the prepared formula stored? 
Prompt when necessary. 
Room; covered = 1 
Room; uncovered =  2 
Refrigerator = 3 
Flask: cooled first = 4   
Do not store, give it directly = 5 
Other = 6, specify___________________ 
Don’t know = 9 
21. 
How was the water you use for the child’s 
formula feeds normally prepared? 
One response only, do not prompt. 
Boil before each feed = 1 
Boil once a day and store it: covered = 2 
Filter = 3 
Allow to settle = 4 
Bleach = 5 
Nothing = 6 
Boil, store hot water in flask = 7 
Other = 8, specify: _________________ 
Don’t know = 9 
22. Are you currently receiving formula milk from the 
hospital/clinic for your infant? 
No = 0 
Yes = 1 
23. Since we last saw you have you been to the 
clinic to collect milk and found that they were 
out of stock? 
No = 0 Æ SKIP to Q25
Yes = 1 
24. How many times has this happened since we 
last saw you? ______# of times 
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25. Since we last saw you have you purchased any 
formula milk for your infant? 
No = 0 
Yes = 1 
26. Since we last saw you have you run out of 
formula milk? 
No = 0 Æ SKIP to Q29
Yes = 1 
27. How many days did this last? Days: _________ 
28. 
What did you feed the baby during this time? 









29. Do you have any formula in the house today? No = 0 Yes = 1 
30. Since we last saw you have you ever put your 
baby to the breast e.g. to go to sleep, in bed at 
night time, when crying? 
No = 0 
Yes = 1 
31. Since we last saw you have you seen adverts at 
any health clinic advertising formula milks? 
No = 0 
Yes = 1 
Questions about leaving the child 
32. Have you  been separated from your child since 
we last saw you so that someone else has fed 
the child? 
No = 0 Æ SKIP to Q34
Yes = 1 
33. 
What did they feed the child the last time you 
were away? 
Circle all that apply
a. Water based liquids
b. Milk based liquids/semi-solid feeds
c. My own expressed breast milk
d. The child was “wet nursed” (breastfed by another
woman)
e. Formula milk
f. Food that I chewed for the baby
g. Do not know
h. Other, Specify: ___________________
Last questions about formula and breastfeeding: 
We will now ask you only five more questions about milk feeding
34. 
Which of these medicines is your baby currently 
receiving: 
Please show the mother a range of possible medicines: 
multivitamins, iron drops, nevirapine, cotrimoxazole, TB 
treatment and antibiotics
Circle all that apply







h. Other – specify________________
i. Baby is not currently receiving any medicine
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35. 
How old was the baby when you FIRST 
gave him/her anything other than breast-
milk or medicine? 
# weeks old __________________ 
OR 
Have only given baby breast-milk and medicine since 
birth = 0 Æ END
Unsure = 9 Æ END 
36. 
From the time you woke up yesterday 
morning till you woke up this morning did 
you give your baby any formula milk? 
No = 0 Æ END 
Yes = 1 
37. From the time you woke up yesterday 
morning till you went to bed last night, how 
many times did you feed your baby formula 
milk? 
 _________# of times
38. 
From the time you went to bed last night till 
you woke up this morning, how many times 
did you feed your baby formula milk? 
____________ # of times 
Questions about introduction of complementary foods 
We will now ask you about feeding your baby food other than milk
39. Do you give your baby any meals or snacks besides milk? 
No = 0 Æ END 
Yes = 1 
40. 
At what age did you FIRST give your baby any 
meals or snacks besides milk? 
Choose one option 
a. Within 1 week of birth
b. 1-4 weeks old
c. 1-2 months old
d. 2-3 months old
e. 4-5 months old
f. 6 months old




How many times PER DAY do you usually feed 
your baby food other than milk? (both snacks and 
meals) 
#__________________times per day 
42. 
How many times did you give your baby food 
other than milk yesterday? (both snacks and meals) #________________ times per day 
43. 
How much food (other than milk) does your 
baby usually eat per meal?** Please show mother
the study-specific cups (full cup, half cup, quarter 
cup) and teaspoon  
a. A teaspoon or less
b. ¼ - ½  cup
c. ½ - 1 cup
d. >1 cup
e. Other, please specify: _______________
f. Unsure
Date completed: __ __ /__ __ __ / __ __ __ __   Signed counsellor completing CRF: _________________ 
Date of QC: __ __ /__ __ __ / __ __ __ __      Signed measurement nurse: _________________ 
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Phase 2 Informed Consent Form 
TITLE OF RESEARCH: Strategies to optimize antiretroviral therapy 
services for maternal & child health: the MCH-
ART study  
WHAT IS THE PURPOSE OF THIS STUDY? 
We are from the University of Cape Town and ICAP at Columbia University. You are being 
asked to take part in a study that is being conducted at the Gugulethu Midwife Obstetric Unit 
(MOU).  The purpose of this study is to understand how to improve health care services for HIV-
positive women during their pregnancy and after they deliver the baby.  
We know that it is important for their own health as well as the health of their baby, that HIV-
positive women receive the HIV care and treatment that they need both during and after delivery. 
Information learned in this study will help us to improve HIV services for pregnant women. 
You are being asked to take part in this study because you are a pregnant woman with known 
HIV infection who is about to start taking HIV drugs (antiretroviral therapy) and you took part in 
the first phase of the study. The purpose of this consent form is to give you information to help 
you decide if you want to take part in the next phase of this study.  
WHAT DO I HAVE TO DO IF I AGREE TO TAKE PART? 
If you agree to take part, you will come in for up to 3 visits. These visits will take place today 
while you are in the clinic, when you are getting close to delivering your baby and within one 
week of delivering your baby. These study visits are separate from the usual clinic visits that you 
will have for your pregnancy and HIV care. Study visits will be timed so that they take place on 
the same days that you come in for your usual pregnancy and/or HIV care.Each visit will take 
about 30-45 minutes. 
At the two visits that are conducted while you are pregnant, you will do the following: 
• Answer questions about your recent pregnancy- and HIV-related health care, HIV
disclosure, and use of HIV drugs (including side effects and adherence).
o At different visits, we will ask you additional questions about HIV, stigma, social
support, infant feeding practices, family planning, experiences of partner
violence, and mental health (including drug and alcohol use).
• Have 5mLs (1 teaspoon) of blood drawn from your arm each time
One-week after delivery 
One week after you give birth to your baby, you will come to the clinic for a visit that will 
include the following: 
• Answer questions about your recent pregnancy- and HIV-related health care, HIV
disclosure, and use of HIV drugs (including side effects and adherence).
o At this visit, we will ask you additional questions about family planning after
delivery, how you felt about the HIV care that you received, infant feeding
practices and infant health and health care.
• Have 5mLs (1 teaspoon) of blood drawn from your arm
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NOTE: The blood that is drawn today will be stored and used to check your viral load (this is the 
amount of HIV in your blood) at a later time. Results from these tests will not be available to 
you, the clinic, or the study staff. When the health care providers at the clinic need to check your 
viral load, they will take a separate blood specimen. When it is stored, your blood and test results 
will not have your name or any other way of identifying you attached to it. 
Follow-up of missed visits 
You will be asked to provide contact information so that we may get in touch with you during 
the study. Study staff will talk with you about the best way to contact you. In the event that you 
miss one of the scheduled study visits, a member of the study staff will contact you in order to 
find another day and time to complete your visit. If you repeatedly miss study visits or the staff is 
unable to contact you using the information that you provide, it may be necessary to visit you at 
home in order to reschedule the missed study visit. 
Contact for future study 
After the completion of the visit one week after delivery, it is possible that we will contact you 
again at your next clinic visit or at another time in the future to take part in additional research 
studies. At that time, you would be asked to review and sign another consent form. You can 
choose to not take part in any future studies if you are asked. You will be asked to provide 
contact information so that we may get in touch with you regarding additional research studies. 
Study staff will talk with you about the best way to contact you.  
WHAT ARE THE POTENTIAL RISKS? 
You may feel uncomfortable about some of the personal questions you are asked.  You may 
refuse to answer any question that you do not want to answer.  There is some risk in sharing 
personal and medical information.  We will be careful to keep all your information as private as 
possible.   
Drawing blood is normally done as part of routine medical care and presents a slight risk of 
discomfort. Experienced staff will draw blood under sterile conditions in order to protect you 
against these risks. 
WHAT ARE THE POTENTIAL BENEFITS? 
There is no direct benefit to you if you take part in this study. The information gained in this 
study may help to improve ART services for HIV-infected pregnant women in Cape Town, the 
Western Cape Province, and across South Africa. 
WHAT ARE THE ALTERNATIVES TO TAKING PART?  
The alternative to taking part in this study is to continue with your usual care at the MOU. 
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WHAT ABOUT CONFIDENTIALITY? 
If you agree to take part, all information collected during the study will be kept strictly 
confidential. Your name will not be written on the study forms and will not be used in 
connection with any information or lab specimens that are collected as part of the study. 
All study materials will be stored in locked filing cabinets. Only study staff and personnel 
involved in routine audits will have access to these materials. All staff involved in data collection 
and management will get specific training in confidentiality. 
Even with these procedures in place, if the study staff learns that you are a risk to yourself or 
someone else or of possible child abuse and/or neglect, study staff will tell the proper authorities. 
WILL I BE GIVEN ANYTHING FOR TAKING PART? 
At the end of each visit, you will be given R20 in cash to cover the transport cost to your next 
scheduled study visit, and anR80grocery voucher. You will also receive a small gift for the first 
visit after birth and refreshments will be provided at all visits. 
ARE THERE ANY COSTS? 
There is no cost for being in this study. 
CAN I LEAVE THE STUDY? 
You have the right to decide not to not take part in the study, to refuse to answer any questions, 
or to withdraw from the study at any time without any penalty.  It will have no effect on the care 
that you receive at the Gugulethu MOU or any other health facility. 
FUTURE USE OF SPECIMENS: 
If you agree, any leftover blood from the samples you have provided for this research project 
may be used for future HIV related research. It is possible that these stored samples may be 
tested to see if the HIV in your blood is resistant to any types of HIV medications or to look at 
other questions related to HIV. 
At this time, we cannot provide details of when this testing may be conducted. However, 
additional testing will not be done using these stored samples without the approval of the 
appropriate ethics committees involved in this research. 
If you agree to let us keep your stored samples for future research, they may be kept in a locked 
freezer for up to 5 years. If we do use your samples in the future, your name or other identifiers 
will not be included with this information (as with the rest of the information we collect for this 
study). 
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Please initial below to indicate whether or not you give permission for your specimens to be used 
for future research. You may still remain in the study, no matter which you choose.  
______ (initial) I agree to have my blood stored for future research. 
______ (initial) I agree to have my blood stored for future research related to this study ONLY. 
______ (initial) I do NOT agree to the storage of my blood for future use. 
DO YOU HAVE ANY QUESTIONS? 
If there is anything that is unclear or if you need further information, please ask us and we will 
provide it.  
Do you have any questions? 
FOR ADDITIONAL INFORMATION: 
If you have any questions or have any problems while taking part in this research study, you 
should contact: 
Dr Landon Myer Dr Elaine Abrams 
School of Public Health and Family Medicine ICAP, Columbia University 
Faculty of Health Sciences, University of 
Cape Town 
Mailman School of Public Health 
College of Physicians and Surgeons 
Tel: 021 406 6661 
Email: Landon.Myer@uct.ac.za 
Tel: +1 212 342 0543 
Email: eja1@columbia.edu 
If you have any questions about your rights as a research participant, you may contact the 
following member of the ethics committee: 
Prof Marc Blockman  Columbia University Medical Center IRB 
Chair, Human Research Ethics Committee Tel: +1 212 305 5883 
Faculty of Health Sciences, University of Cape 
Town 
Tel: 021 406 6338 
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CONSENT STATEMENT:   
I have read this form, or someone has read it to me.  I have been offered a copy of this consent 
form. I was encouraged and given time to ask questions.  I agree to be in this study.  I know that 
after choosing to be in this study, I may withdraw at any time.  My being in the study is 
voluntary. I understand that whether or not I participate will not affect my health care services 
received today, or at any time in the future. 
Please indicate your consent with your signature.  
Volunteer’s name _____________________________________ 
_____________________________________________________ 
Signature of Volunteer Date   
Staff member’s name ____________________________________ 
_____________________________________________________ 
Signature of study staff    Date 
If the volunteer is unable to read or write the entire counselling process must be observed 
by an independent witness who can then confirm the procedure once the she has given 
consent. 
Fingerprint of volunteer: 
Witness: 
I confirm that I am independent of the study and that I witnessed the entire informed consent 
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TITLE OF RESEARCH: Strategies to optimize antiretroviral therapy 
services for maternal & child health: the MCH-
ART study  
WHAT IS THE PURPOSE OF THIS STUDY? 
We are from the University of Cape Town and ICAP at Columbia University. You are being 
asked to take part in a study that is being conducted at the Gugulethu Midwife Obstetric Unit 
(MOU). The purpose of this study is to compare two different ways of providing HIV treatment 
to women after they deliver a baby.   
We know that it is important for their own health as well as the health of their baby, that HIV-
positive women receive the HIV care and treatment that they need both during and after delivery. 
Information learned in this study will help us to improve HIV services for pregnant women. 
You are being asked to take part in this study because you are woman with known HIV infection 
who is currently breastfeeding a baby and who is taking HIV drugs. In addition, you have taken 
part in the previous phases of this study. The purpose of this consent form is to give you 
information to help you decide if you want to continue to take part in the last phase of this study. 
WHAT DO I HAVE TO DO IF I AGREE TO TAKE PART? 
If you agree to take part, you will be randomized (like a flip of a coin) to one of two places to 
receive your ART, as described below:  
1. MCH-focused ART services group: Women assigned to this group will continue to
receive HIV care and medicines here, at the MOU, as they did during their pregnancy.
Their babies will also receive their routine baby care here at the MOU. When they have
stopped breastfeeding, women in this group will be referred to their nearest general ART
clinic, and their babies to their nearest City of Cape Town clinic for routine baby care
2. General ART services group: Women assigned to this group will be referred to the
nearest ART clinic for HIV care and to continue their HIV medicines. Their babies will
be referred to their nearest clinic for routine baby care.
This is currently the standard of care for all HIV-positive women and their babies
attending the MOU.
“Randomized” means that you will have a 50% chance of being in the group that will stay at the 
MOU to receive care.  You will also have a 50% chance of being in the group that gets referred 
to an ART clinic. Neither the study staff nor you can choose which group you will be assigned 
to. The decisions are made by a computer and put into an envelope. The staff does not know 
which group is in each envelope. 
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This randomization will occur today and you and your baby will then come in for up to 6 
additional study measurement visits at 6 weeks after delivery and 3, 6, 9, 12 and 18 months after 
delivery. These study visits are separate from the usual clinic visits that you will have for your 
postpartum and HIV care. Study visits will be timed so that they take place on the same days that 
you come in for your usual postpartum and/or HIV care. Each visit will take about 30-60 
minutes. 
These visits will include the following: 
x Answer questions about your recent pregnancy- and HIV-related health care, HIV 
disclosure, and use of HIV drugs (including side effects and adherence). 
o At selected visits, we will ask you additional questions about HIV, stigma, and
mental health (including drug and alcohol use), family planning, infant feeding
practices, infant health and health care and how you feel about the HIV care that
you have received.
x Have 5mLs (1 teaspoon) of blood drawn from your arm  
x Measurement of weight, length, head circumference and mid-upper arm circumference of 
your baby. 
x Measurement of your height at the first visit and your weight and mid-upper arm 
circumference at all study visits 
NOTE: The blood that is drawn at each visit will be stored and used to check your viral load (this 
is the amount of HIV in your blood) at a later time. Results from these tests will not be available 
to you, the clinic, or the study staff. When the health care providers at the clinic need to check 
your viral load, they will take a separate blood specimen. When it is stored, your blood and test 
results will not have your name or any other way of identifying you attached to it. 
At both the 12 and 18 month visits, we will also draw blood from your baby: 
x Baby will undergo a blood draw to collect up to 5ml of blood (no more than 1 teaspoon). 
x This blood will be used to check your baby’s HIV status. 
o We will return the results of this test to you as soon as it is available.
Follow-up of missed visits 
You will be asked to provide contact information so that we may get in touch with you during 
the study. Study staff will talk with you about the best way to contact you. In the event that you 
miss one of the scheduled study visits, a member of the study staff will contact you in order to 
find another day and time to complete your visit. If you repeatedly miss study visits or the staff is 
unable to contact you using the information that you provide, it may be necessary to visit you at 
home in order to reschedule the missed study visit. 
Contact for future study 
After the completion of your last visit at 18 months postpartum, it is possible that we will 
contact you again at your next clinic visit or at another time in the future to take part in 
additional research studies. At that time, you would be asked to review and sign another consent 
form. You can choose to not take part in any future studies if you are asked. You will be asked to 
provide contact information so that we may get in touch with you regarding additional research 
studies. Study staff will talk with you about the best way to contact you.  
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WHAT ARE THE POTENTIAL RISKS? 
You may feel uncomfortable about some of the personal questions you are asked.  You may 
refuse to answer any question that you do not want to answer.  There is some risk in sharing 
personal and medical information.  We will be careful to keep all your information as private as 
possible.   
Drawing blood is normally done as part of routine medical care and presents a slight risk of 
discomfort. Experienced staff will draw blood under sterile conditions in order to protect you 
against these risks. 
WHAT ARE THE POTENTIAL BENEFITS? 
There is no direct benefit to you if you take part in this study, but if we identify any health care 
problem for you or your baby during the course of the study, we will make sure you are referred 
to the appropriate health care services. In addition, the information gained in this study may help 
to improve ART services for HIV-infected pregnant women in Cape Town, the Western Cape 
Province, and across South Africa. 
WHAT ARE THE ALTERNATIVES TO TAKING PART?
The alternative to taking part in this study is to continue with the standard of care for all HIV-
positive pregnant women, which means you will be referred from the MOU to your nearest 
general ART clinic, and your baby will be referred to your nearest clinic for routine baby care, as 
soon as possible.  
WHAT ABOUT CONFIDENTIALITY? 
If you agree to take part, all information collected during the study will be kept strictly 
confidential. Your name will not be written on the study forms and will not be used in 
connection with any information or lab specimens that are collected as part of the study. 
All study materials will be stored in locked filing cabinets. Only study staff and personnel 
involved in routine audits will have access to these materials. All staff involved in data collection 
and management will get specific training in confidentiality. 
Even with these procedures in place, if the study staff learns that you are a risk to yourself or 
someone else or of possible child abuse and/or neglect, study staff will tell the proper authorities. 
WHAT ABOUT INSURANCE? 
There are no experimental medicines being used in this study. Therefore no insurance has been 
obtained. However you will be protected in terms of the study staffs’ personal malpractice 
insurance or that of the university in the event of injury or illness that is caused by you taking 
part in this study. 
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If you sign this form, you do not give up any of the legal rights that you and your child have as 
research participants. 
WILL I BE GIVEN ANYTHING FOR TAKING PART? 
At the end of each visit, you will be given R20 in cash to cover the transport cost to your next 
scheduled study visit, and an R80 grocery voucher. Refreshments will be provided at all visits. 
You will also receive a small gift, up to the value of R50, at the final study visit when your baby 
is 12 months old.
ARE THERE ANY COSTS? 
There is no cost for being in this study. 
CAN I LEAVE THE STUDY? 
You have the right to decide not to not take part in the study, to refuse to answer any questions, 
or to withdraw from the study at any time without any penalty.  It will have no effect on the care 
that you receive at the Gugulethu MOU or any other health facility. 
FUTURE USE OF SPECIMENS: 
If you agree, any left over blood from the samples you have provided for this research project 
and the sample taken from your baby at the 12 and 18 month study visit, may be used for future 
HIV and maternal and child health related research. It is possible that these stored samples may 
be tested to see if the HIV in your blood is resistant to any types of HIV medications or to look at 
other questions related to HIV. It is also possible that the stored blood from you and your baby 
may be used to look at other questions related to maternal and child health. 
At this time, we cannot provide details of when this testing may be conducted. However, 
additional testing will not be done using these stored samples without the approval of the 
appropriate ethics committees involved in this research. 
If you agree to let us keep your and/or your baby’s stored samples for future research, they will 
be kept in a locked freezer for up to 5 years. If we do use the samples in the future, your name, 
your baby’s name or other identifiers will not be included with this information (as with the rest 
of the information we collect for this study). 
Please initial below to indicate whether or not you give permission for your and/or your baby’s 
specimens to be used for future research. You may still remain in the study, no matter which you 
choose. 
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Consent for storage of your blood: 
______ (initial) I agree to have my blood stored for future research. 
______ (initial) I agree to have my blood stored for future research related to this study ONLY. 
______ (initial) I do NOT agree to the storage of my blood for future use. 
Consent for storage of your baby’s blood taken at the 12 and 18 month visit: 
______ (initial) I agree to have my baby’s blood stored for future research.  
______ (initial) I agree to have my baby’s blood stored for future research related to this study 
ONLY. 
______ (initial) I do NOT agree to the storage of my baby’s blood for future use. 
DO YOU HAVE ANY QUESTIONS? 
If there is anything that is unclear or if you need further information, please ask us and we will 
provide it.  
Do you have any questions? 
FOR ADDITIONAL INFORMATION: 
If you have any questions or have any problems while taking part in this research study, you 
should contact: 
Dr Landon Myer Dr Elaine Abrams 
School of Public Health and Family Medicine ICAP, Columbia University 
Faculty of Health Sciences, University of 
Cape Town 
Mailman School of Public Health 
College of Physicians and Surgeons 
Tel: 021 406 6661 
Email: Landon.Myer@uct.ac.za 
Tel: +1 212 342 0543 
Email: eja1@columbia.edu 
If you have any questions about your rights as a research participant, you may contact the 
following member of the ethics committee: 
Prof Marc Blockman  Columbia University Medical Center IRB 
Chair, Human Research Ethics Committee Tel: +1 212 305 5883 
Faculty of Health Sciences, University of Cape 
Town 
Tel: 021 406 6338 
IRB-AAAK8059
     for use until: 10/05/2016
IRB Approval Date: 10/06/2015
Phase 3 Informed Consent Form 
Page 6 of 6 
Version 3.3 8 Jan 2015 
CONSENT STATEMENT:   
I have read this form, or someone has read it to me.  I have been offered a copy of this consent 
form. I was encouraged and given time to ask questions.  I agree to be in this study.  I know that 
after choosing to be in this study, I may withdraw at any time.  My being in the study is 
voluntary. I understand that whether or not I participate will not affect my health care services 
received today, or at any time in the future. 
Please indicate your consent with your signature. 
Volunteer’s name ______________________________________ 
_____________________________________________________ 
Signature of Volunteer Date   
Staff member’s name____________________________________ 
_____________________________________________________ 
Signature of study staff    Date 
If the volunteer is unable to read or write the entire counselling process must be observed by an 
independent witness who can then confirm the procedure once the she has given consent. 
Fingerprint of volunteer: 
Witness: 
I confirm that I am independent of the study and that I witnessed the entire informed consent 






     for use until: 10/05/2016
IRB Approval Date: 10/06/2015
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International Journal of Breastfeeding 
manuscript instructions
General formatting guidelines 
x  Preparing main manuscript text 
x  Preparing illustrations and figures 
x  Preparing tables 
x  Preparing additional files 
Preparing main manuscript text 
Quick points: 
x Use double line spacing 
x Include line and page numbering 
x Use SI units: Please ensure that all special characters used are 
embedded in the text, otherwise they will be lost during conversion to 
PDF 
x Do not use page breaks in your manuscript 
File formats 
The following word processor file formats are acceptable for the main 
manuscript document: 
x Microsoft word (DOC, DOCX) 
x Rich text format (RTF) 
x TeX/LaTeX (use BioMed Central's TeX template) 
Please note: editable files are required for processing in production. If 
your manuscript contains any non-editable files (such as PDFs) you will 
be required to re-submit an editable file when you submit your revised 
manuscript, or after editorial acceptance in case no revision is 
necessary. 
Note that figures must be submitted as separate image files, not as part 
of the submitted manuscript file. For more information, see Preparing 
figures below. 
Additional information for TeX/LaTeX users 
Please use BioMed Central's TeX template and BibTeX stylefile if you 
use TeX format. When submitting TeX submissions, please submit your 
TeX file as the main manuscript file and your bib/bbl file as a dependent 
file. Please also convert your TeX file into a PDF and submit this PDF as 
an additional file with the name 'Reference PDF'. This PDF will be used 
by our production team as a reference point to check the layout of the 
article as the author intended. Please also note that all figures must be 
coded at the end of the TeX file and not inline. 
All relevant editable source files must be uploaded during the 
submission process. Failing to submit these source files will cause 
unnecessary delays in the production process. 
TeX templates 
BioMedCentral_article (ZIP format) - preferred template 
Springer article svjour3 (ZIP format) 
birkjour (Birkhäuser, ZIP format) 
article (part of the standard TeX distribution) 
amsart (part of the standard TeX distribution) 
Style and language 
For editors and reviewers to accurately assess the work presented in 
your manuscript you need to ensure the English language is of 
sufficient quality to be understood. If you need help with writing in 
English you should consider: 
x Visiting the English language tutorial which covers the common 
mistakes when writing in English. 
x Asking a colleague who is a native English speaker to review your 
manuscript for clarity. 
x Using a professional language editing service where editors will 
improve the English to ensure that your meaning is clear and identify 
problems that require your review. Two such services are provided by 
our affiliates Nature Research Editing Service and American Journal 
Experts. 
Please note that the use of a language editing service is not a 
requirement for publication in the journal and does not imply or 
guarantee that the article will be selected for peer review or accepted. 
Data and materials 
For all journals, BioMed Central strongly encourages all datasets on 
which the conclusions of the manuscript rely to be either deposited in 
publicly available repositories (where available and appropriate) or 
presented in the main paper or additional supporting files, in machine-
readable format (such as spread sheets rather than PDFs) whenever 
possible. Please see the list of recommended repositories in our 
editorial policies. 
For some journals, deposition of the data on which the conclusions of 
the manuscript rely is an absolute requirement. Please check the 
Instructions for Authors for the relevant journal and article type for 
journal specific policies. 
For all manuscripts, information about data availability should be 
detailed in an ‘Availability of data and materials’ section. For more 
information on the content of this section, please see the Declarations 
section of the relevant journal’s Instruction for Authors. For more 
information on BioMed Centrals policies on data availability, please see 
our [editorial policies]. 
Formatting the 'Availability of data and materials' section of your manuscript 
The following format for the 'Availability of data and materials section 
of your manuscript should be used: 
"The dataset(s) supporting the conclusions of this article is(are) 
available in the [repository name] repository, [unique persistent 
identifier and hyperlink to dataset(s) in http:// format]." 
The following format is required when data are included as additional 
files: 
"The dataset(s) supporting the conclusions of this article is(are) 
included within the article (and its additional file(s))." 
BioMed Central endorses the Force 11 Data Citation Principles and 
requires that all publicly available datasets be fully referenced in the 
reference list with an accession number or unique identifier such as a 
DOI. 
For databases, this section should state the web/ftp address at which 
the database is available and any restrictions to its use by non-
academics. 
For software, this section should include: 
x Project name: e.g. My bioinformatics project 
x Project home page: e.g. http://sourceforge.net/projects/mged 
x Archived version: DOI or unique identifier of archived software or code 
in repository (e.g. enodo) 
x Operating system(s): e.g. Platform independent 
x Programming language: e.g. Java 
x Other requirements: e.g. Java 1.3.1 or higher, Tomcat 4.0 or higher 
x License: e.g. GNU GPL, FreeBSD etc. 
x Any restrictions to use by non-academics: e.g. licence needed 
Information on available repositories for other types of scientific data, 
including clinical data, can be found in our editorial policies. 
References 
See our editorial policies for author guidance on good citation practice. 
All references, including URLs, must be numbered consecutively, in 
square brackets, in the order in which they are cited in the text, 
followed by any in tables or legends. The reference numbers must be 
finalized and the reference list fully formatted before submission. For 
further information including example references please read our 
reference preparation guidelines. 
What should be cited? 
Only articles, clinical trial registration records and abstracts that have 
been published or are in press, or are available through public e-
print/preprint servers, may be cited. 
Unpublished abstracts, unpublished data and personal 
communications should not be included in the reference list, but may 
be included in the text and referred to as "unpublished observations" 
or "personal communications" giving the names of the involved 
researchers. Obtaining permission to quote personal communications 
and unpublished data from the cited colleagues is the responsibility of 
the author. Footnotes are not allowed, but endnotes are permitted. 
Journal abbreviations follow Index Medicus/MEDLINE. 
Any in press articles cited within the references and necessary for the 
reviewers' assessment of the manuscript should be made available if 
requested by the editorial office. 
How to format your references 
Examples of the BioMed Central reference style are shown below. 
Please ensure that the reference style is followed precisely; if the 
references are not in the correct style, they may need to be retyped and 
carefully proofread. 
Web links and URLs: All web links and URLs, including links to the 
authors' own websites, should be given a reference number and 
included in the reference list rather than within the text of the 
manuscript. They should be provided in full, including both the title of 
the site and the URL, as well as the date the site was accessed, in the 
following format: The Mouse Tumor Biology Database. 
http://tumor.informatics.jax.org/mtbwi/index.do. Accessed 20 May 
2013. If an author or group of authors can clearly be associated with a 
web link, such as for weblogs, then they should be included in the 
reference. 
Authors may wish to make use of reference management software to 
ensure that reference lists are correctly formatted. 
Example reference style: 
Article within a journal 
Smith JJ. The world of science. Am J Sci. 1999;36:234-5. 
Article within a journal (no page numbers) 
Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg 
R, Tjønneland A, et al. Meat consumption and mortality - results from 
the European Prospective Investigation into Cancer and Nutrition. BMC 
Med. 2013;11:63. 
Article within a journal by DOI 
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine 
production. Dig J Mol Med. 2000; doi:10.1007/s801090000086. 
Article within a journal supplement 
Frumin AM, Nussbaum J, Esposito M. Functional asplenia: 
demonstration of splenic activity by bone marrow scan. Blood 1979;59 
Suppl 1:26-32. 
Book chapter, or an article within a book 
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. 
In: Bourne GH, Danielli JF, Jeon KW, editors. International review of 
cytology. London: Academic; 1980. p. 251-306. 
OnlineFirst chapter in a series (without a volume designation but with a 
DOI) 
Saito Y, Hyuga H. Rate equation approaches to amplification of 
enantiomeric excess and chiral symmetry breaking. Top Curr Chem. 
2007. doi:10.1007/128_2006_108. 
Complete book, authored 
Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the 
management of common illness. 3rd ed. Oxford: Blackwell Science; 
1998. 
Online document 
Doe J. Title of subordinate document. In: The dictionary of substances 
and their effects. Royal Society of Chemistry. 1999. 
http://www.rsc.org/dose/title of subordinate document. Accessed 15 
Jan 1999. 
Online database 
Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. 
http://www.healthwise.org. Accessed 21 Sept 1998. 
Supplementary material/private homepage 
Doe J. Title of supplementary material. 2000. 
http://www.privatehomepage.com. Accessed 22 Feb 2000. 
University site 
Doe, J: Title of preprint. http://www.uni-heidelberg.de/mydata.html 
(1999). Accessed 25 Dec 1999. 
FTP site 
Doe, J: Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt 
(1999). Accessed 12 Nov 1999. 
Organization site 
ISSN International Centre: The ISSN register. http://www.issn.org (2006). 
Accessed 20 Feb 2007. 
Dataset with persistent identifier 
Zheng L-Y, Guo X-S, He B, Sun L-J, Peng Y, Dong S-S, et al. Genome data 
from sweet and grain sorghum (Sorghum bicolor). GigaScience 
Database. 2011. http://dx.doi.org/10.5524/100012. 
Preparing figures 
Back to top 
When preparing figures, please follow the formatting instructions 
below. 
x Figures should be provided as separate files, not embedded in the main 
manuscript file. 
x Each figure of a manuscript should be submitted as a single file that fits 
on a single page in portrait format. 
x Tables should NOT be submitted as figures but should be included in 
the main manuscript file. 
x Multi-panel figures (those with parts a, b, c, d etc.) should be submitted 
as a single composite file that contains all parts of the figure. 
x Figures should be numbered in the order they are first mentioned in 
the text, and uploaded in this order. 
x Figures should be uploaded in the correct orientation. 
x Figure titles (max 15 words) and legends (max 300 words) should be 
provided in the main manuscript, not in the graphic file. 
x Figure keys should be incorporated into the graphic, not into the legend 
of the figure. 
x Each figure should be closely cropped to minimize the amount of white 
space surrounding the illustration. Cropping figures improves accuracy 
when placing the figure in combination with other elements when the 
accepted manuscript is prepared for publication on our site. For more 
information on individual figure file formats, see our detailed 
instructions. 
x Individual figure files should not exceed 10 MB. If a suitable format is 
chosen, this file size is adequate for extremely high quality figures. 
x Please note that it is the responsibility of the author(s) to obtain 
permission from the copyright holder to reproduce figures (or tables) 
that have previously been published elsewhere. In order for all figures 
to be open access, authors must have permission from the rights 
holder if they wish to include images that have been published 
elsewhere in non open access journals. Permission should be indicated 
in the figure legend, and the original source included in the reference 
list. 
Figure file types 
We accept the following file formats for figures: 
x EPS (suitable for diagrams and/or images) 
x PDF (suitable for diagrams and/or images) 
x Microsoft Word (suitable for diagrams and/or images, figures must be a 
single page) 
x PowerPoint (suitable for diagrams and/or images, figures must be a 
single page) 
x TIFF (suitable for images) 
x JPEG (suitable for photographic images, less suitable for graphical 
images) 
x PNG (suitable for images) 
x BMP (suitable for images) 
x CDX (ChemDraw - suitable for molecular structures) 
For information and suggestions of suitable file formats for specific 
figure types, please see our author academy. 
Figure size and resolution 
Figures are resized during publication of the final full text and PDF 
versions to conform to the BioMed Central standard dimensions, which 
are detailed below. 
Figures on the web: 
x width of 600 pixels (standard), 1200 pixels (high resolution). 
Figures in the final PDF version: 
x width of 85 mm for half page width figure 
x width of 170 mm for full page width figure 
x maximum height of 225 mm for figure and legend 
x image resolution of approximately 300 dpi (dots per inch) at the final 
size 
Figures should be designed such that all information, including text, is 
legible at these dimensions. All lines should be wider than 0.25 pt when 
constrained to standard figure widths. All fonts must be embedded. 
Figure file compression 
x Vector figures should if possible be submitted as PDF files, which are 
usually more compact than EPS files. 
x TIFF files should be saved with LZW compression, which is lossless 
(decreases file size without decreasing quality) in order to minimize 
upload time. 
x JPEG files should be saved at maximum quality. 
x Conversion of images between file types (especially lossy formats such 
as JPEG) should be kept to a minimum to avoid degradation of quality. 
If you have any questions or are experiencing a problem with figures, 
please contact the customer service team at info@biomedcentral.com. 
Preparing tables 
Back to top 
When preparing tables, please follow the formatting instructions below. 
x Tables should be numbered and cited in the text in sequence using 
Arabic numerals (i.e. Table 1, Table 2 etc.). 
x Tables less than one A4 or Letter page in length can be placed in the 
appropriate location within the manuscript. 
x Tables larger than one A4 or Letter page in length can be placed at the 
end of the document text file. Please cite and indicate where the table 
should appear at the relevant location in the text file so that the table 
can be added in the correct place during production. 
x Larger datasets, or tables too wide for A4 or Letter landscape page can 
be uploaded as additional files. Please see [below] for more 
information. 
x Tabular data provided as additional files can be uploaded as an Excel 
spreadsheet (.xls ) or comma separated values (.csv). Please use the 
standard file extensions. 
x Table titles (max 15 words) should be included above the table, and 
legends (max 300 words) should be included underneath the table. 
x Tables should not be embedded as figures or spreadsheet files, but 
should be formatted using ‘Table object’ function in your word 
processing program. 
x Color and shading may not be used. Parts of the table can be 
highlighted using superscript, numbering, lettering, symbols or bold 
text, the meaning of which should be explained in a table legend. 
x Commas should not be used to indicate numerical values. 
If you have any questions or are experiencing a problem with tables, 
please contact the customer service team at info@biomedcentral.com. 
Preparing additional files 
Back to top 
As the length and quantity of data is not restricted for many article 
types, authors can provide datasets, tables, movies, or other 
information as additional files. 
All Additional files will be published along with the accepted article. Do 
not include files such as patient consent forms, certificates of language 
editing, or revised versions of the main manuscript document with 
tracked changes. Such files, if requested, should be sent by email to the 
journal’s editorial email address, quoting the manuscript reference 
number. Please do not send patient consent forms unless requested. 
Results that would otherwise be indicated as "data not shown" should 
be included as additional files. Since many web links and URLs rapidly 
become broken, BioMed Central requires that supporting data are 
included as additional files, or deposited in a recognized repository. 
Please do not link to data on a personal/departmental website. Do not 
include any individual participant details. The maximum file size for 
additional files is 20 MB each, and files will be virus-scanned on 
submission. Each additional file should be cited in sequence within the 
main body of text. 
If additional material is provided, please list the following information in 
a separate section of the manuscript text: 
x File name (e.g. Additional file 1) 
x File format including the correct file extension for example .pdf, .xls, 
.txt, .pptx (including name and a URL of an appropriate viewer if format 
is unusual) 
x Title of data 
x Description of data 
Additional files should be named "Additional file 1" and so on and 
should be referenced explicitly by file name within the body of the 
article, e.g. 'An additional movie file shows this in more detail [see 
Additional file 1]'. 
For further guidance on how to use Additional files or 
recommendations on how to present particular types of data or 
information, please see How to use additional files. 
Preparing your manuscript 
Research article 
Criteria 
Research articles should report on original primary research. 
International Breastfeeding Journal strongly encourages that all 
datasets on which the conclusions of the paper rely should be available 
to readers. We encourage authors to ensure that their datasets are 
either deposited in publicly available repositories (where available and 
appropriate) or presented in the main manuscript or additional 
supporting files whenever possible. Please see Springer 
Nature’s information on recommended repositories. Where a widely 
established research community expectation for data archiving in 
public repositories exists, submission to a community-endorsed, public 
repository is mandatory. A list of data where deposition is required, 
with the appropriate repositories, can be found on the Editorial Policies 
Page. 
International Breastfeeding Journal does not accept for publication any 
manuscript that has received funding, sponsorship or any other means 
of support from infant formula manufacturers. 
Preparing your manuscript 
The information below details the section headings that you should 
include in your manuscript and what information should be within each 
section. 
Please note that your manuscript must include a 'Declarations' section 
including all of the subheadings (please see below for more 
information). 
Title page
The title page should: 
x present a title that includes, if appropriate, the study design e.g.: 
o "A versus B in the treatment of C: a randomized controlled trial", "X is a
risk factor for Y: a case control study", "What is the impact of factor X on
subject Y: A systematic review"
o or for non-clinical or non-research studies a description of what the
article reports
x list the full names, institutional addresses and email addresses for all 
authors 
o if a collaboration group should be listed as an author, please list the
Group name as an author. If you would like the names of the individual
members of the Group to be searchable through their individual
PubMed records, please include this information in the
“Acknowledgements” section in accordance with the instructions below
x indicate the corresponding author 
Abstract
The Abstract should not exceed 350 words. Please minimize the use of 
abbreviations and do not cite references in the abstract. Reports of 
randomized controlled trials should follow the CONSORT extension for 
abstracts. The abstract must include the following separate sections: 
x Background: the context and purpose of the study 
x Methods: how the study was performed and statistical tests used 
x Results: the main findings 
x Conclusions: brief summary and potential implications 
x Trial registration: If your article reports the results of a health care 
intervention on human participants, it must be registered in an 
appropriate registry and the registration number and date of 
registration should be in stated in this section. If it was not registered 
prospectively (before enrollment of the first participant), you should 
include the words 'retrospectively registered'. See our editorial 
policies for more information on trial registration 
Keywords
Three to ten keywords representing the main content of the article. 
Background
The Background section should explain the background to the study, its 
aims, a summary of the existing literature and why this study was 
necessary or its contribution to the field. 
Methods
The methods section should include: 
x the aim, design and setting of the study 
x the characteristics of participants or description of materials 
x a clear description of all processes, interventions and comparisons. 
Generic drug names should generally be used. When proprietary 
brands are used in research, include the brand names in parentheses 
x the type of statistical analysis used, including a power calculation if 
appropriate 
Results
This should include the findings of the study including, if appropriate, 
results of statistical analysis which must be included either in the text 
or as tables and figures. 
Discussion
This section should discuss the implications of the findings in context of 
existing research and highlight limitations of the study. 
Conclusions
This should state clearly the main conclusions and provide an 
explanation of the importance and relevance of the study reported. 
List of abbreviations
If abbreviations are used in the text they should be defined in the text 
at first use, and a list of abbreviations should be provided. 
Declarations
All manuscripts must contain the following sections under the heading 
'Declarations': 
x Ethics approval and consent to participate 
x Consent for publication 
x Availability of data and material 
x Competing interests 
x Funding 
x Authors' contributions 
x Acknowledgements 
x Authors' information (optional) 
Please see below for details on the information to be included in these 
sections. 
If any of the sections are not relevant to your manuscript, please 
include the heading and write 'Not applicable' for that section. 
Ethics approval and consent to participate 
Manuscripts reporting studies involving human participants, human 
data or human tissue must: 
x include a statement on ethics approval and consent (even where the 
need for approval was waived) 
x include the name of the ethics committee that approved the study and 
the committee’s reference number if appropriate 
Studies involving animals must include a statement on ethics approval. 
See our editorial policies for more information. 
If your manuscript does not report on or involve the use of any animal 
or human data or tissue, please state “Not applicable” in this section. 
Consent for publication 
If your manuscript contains any individual person’s data in any form 
(including individual details, images or videos), consent for publication 
must be obtained from that person, or in the case of children, their 
parent or legal guardian. All presentations of case reports must have 
consent for publication. 
You can use your institutional consent form or our consent form if you 
prefer. You should not send the form to us on submission, but we may 
request to see a copy at any stage (including after publication). 
See our editorial policies for more information on consent for 
publication. 
If your manuscript does not contain data from any individual person, 
please state “Not applicable” in this section. 
Availability of data and materials 
All manuscripts must include an ‘Availability of data and materials’ 
statement. Data availability statements should include information on 
where data supporting the results reported in the article can be found 
including, where applicable, hyperlinks to publicly archived datasets 
analysed or generated during the study. By data we mean the minimal 
dataset that would be necessary to interpret, replicate and build upon 
the findings reported in the article. We recognise it is not always 
possible to share research data publicly, for instance when individual 
privacy could be compromised, and in such instances data availability 
should still be stated in the manuscript along with any conditions for 
access. 
Data availability statements can take one of the following forms (or a 
combination of more than one if required for multiple datasets): 
x The datasets generated and/or analysed during the current study are 
available in the [NAME] repository, [PERSISTENT WEB LINK TO 
DATASETS] 
x The datasets used and/or analysed during the current study are 
available from the corresponding author on reasonable request. 
x All data generated or analysed during this study are included in this 
published article [and its supplementary information files]. 
x The datasets generated and/or analysed during the current study are 
not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but 
are available from the corresponding author on reasonable request. 
x Data sharing is not applicable to this article as no datasets were 
generated or analysed during the current study. 
x The data that support the findings of this study are available from [third 
party name] but restrictions apply to the availability of these data, 
which were used under license for the current study, and so are not 
publicly available. Data are however available from the authors upon 
reasonable request and with permission of [third party name]. 
x Not applicable. If your manuscript does not contain any data, please 
state 'Not applicable' in this section. 
More examples of template data availability statements, which include 
examples of openly available and restricted access datasets, are 
available here. 
BioMed Central also requires that authors cite any publicly available 
data on which the conclusions of the paper rely in the manuscript. Data 
citations should include a persistent identifier (such as a DOI) and 
should ideally be included in the reference list. Citations of datasets, 
when they appear in the reference list, should include the minimum 
information recommended by DataCite and follow journal style. 
Dataset identifiers including DOIs should be expressed as full URLs. For 
example: 
Hao Z, AghaKouchak A, Nakhjiri N, Farahmand A. Global integrated 
drought monitoring and prediction system (GIDMaPS) data sets. 
figshare. 2014. http://dx.doi.org/10.6084/m9.figshare.853801 
With the corresponding text in the Availability of data and materials 
statement: 
The datasets generated during and/or analysed during the current 
study are available in the [NAME] repository, [PERSISTENT WEB LINK TO 
DATASETS].[Reference number] 
Competing interests 
All financial and non-financial competing interests must be declared in 
this section. 
See our editorial policies for a full explanation of competing interests. If 
you are unsure whether you or any of your co-authors have a 
competing interest please contact the editorial office. 
Please use the authors initials to refer to each author's competing 
interests in this section. 
If you do not have any competing interests, please state "The authors 
declare that they have no competing interests" in this section. 
Funding 
All sources of funding for the research reported should be declared. 
The role of the funding body in the design of the study and collection, 
analysis, and interpretation of data and in writing the manuscript 
should be declared. 
Authors' contributions 
The individual contributions of authors to the manuscript should be 
specified in this section. Guidance and criteria for authorship can be 
found in our editorial policies. 
Please use initials to refer to each author's contribution in this section, 
for example: "FC analyzed and interpreted the patient data regarding 
the hematological disease and the transplant. RH performed the 
histological examination of the kidney, and was a major contributor in 
writing the manuscript. All authors read and approved the final 
manuscript." 
Acknowledgements 
Please acknowledge anyone who contributed towards the article who 
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mentioned in the Acknowledgements section. 
See our editorial policies for a full explanation of acknowledgements 
and authorship criteria. 
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Group authorship (for manuscripts involving a collaboration group): if 
you would like the names of the individual members of a collaboration 
Group to be searchable through their individual PubMed records, 
please ensure that the title of the collaboration Group is included on 
the title page and in the submission system and also include 
collaborating author names as the last paragraph of the 
“Acknowledgements” section. Please add authors in the format First 
Name, Middle initial(s) (optional), Last Name. You can add institution or 
country information for each author if you wish, but this should be 
consistent across all authors. 
Please note that individual names may not be present in the PubMed 
record at the time a published article is initially included in PubMed as 
it takes PubMed additional time to code this information. 
Authors' information 
This section is optional. 
You may choose to use this section to include any relevant information 
about the author(s) that may aid the reader's interpretation of the 
article, and understand the standpoint of the author(s). This may 
include details about the authors' qualifications, current positions they 
hold at institutions or societies, or any other relevant background 
information. Please refer to authors using their initials. Note this 
section should not be used to describe any competing interests. 
Endnotes
Endnotes should be designated within the text using a superscript 
lowercase letter and all notes (along with their corresponding letter) 
should be included in the Endnotes section. Please format this section 
in a paragraph rather than a list. 
References
All references, including URLs, must be numbered consecutively, in 
square brackets, in the order in which they are cited in the text, 
followed by any in tables or legends. The reference numbers must be 
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